U.S. patent application number 10/253977 was filed with the patent office on 2003-04-17 for localized use of nitric oxide-adducts to prevent internal tissue damage.
Invention is credited to Folts, John D., Loscalzo, Joseph, Stamler, Jonathan.
Application Number | 20030072783 10/253977 |
Document ID | / |
Family ID | 23828821 |
Filed Date | 2003-04-17 |
United States Patent
Application |
20030072783 |
Kind Code |
A1 |
Stamler, Jonathan ; et
al. |
April 17, 2003 |
Localized use of nitric oxide-adducts to prevent internal tissue
damage
Abstract
A method for preventing adverse effects associated with the use
of a medical device in a patient by introducing into the patient a
device of which at least a portion includes a prophylactic or
therapeutic amount of a nitric oxide adduct. The nitric oxide
adduct can be present in a matrix coating on a surface of the
medical device; can be coated per se on a surface of the medical
device; can be directly or indirectly bound to reactive sites on a
surface of the medical device; or at least a portion of the medical
device can be formed of a material, such as a polymer, which
includes the nitric oxide adduct. Also disclosed is a method for
preventing adverse effects associated with the use of a medical
device in a patient by introducing the device during a medical
procedure and before or during said procedure locally administering
a nitric oxide adduct to the site of contact of said device with
any internal tissue.
Inventors: |
Stamler, Jonathan; (Chapel
Hill, NC) ; Loscalzo, Joseph; (Dover, MA) ;
Folts, John D.; (Madison, WI) |
Correspondence
Address: |
EDWARD D GRIEFF
HALE & DORR LLP
1455 PENNSYLVANIA AVE, NW
WASHINGTON
DC
20004
US
|
Family ID: |
23828821 |
Appl. No.: |
10/253977 |
Filed: |
September 25, 2002 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10253977 |
Sep 25, 2002 |
|
|
|
09621610 |
Jul 21, 2000 |
|
|
|
6471978 |
|
|
|
|
09621610 |
Jul 21, 2000 |
|
|
|
09433550 |
Nov 4, 1999 |
|
|
|
6174539 |
|
|
|
|
09433550 |
Nov 4, 1999 |
|
|
|
08460465 |
Jun 2, 1995 |
|
|
|
6087479 |
|
|
|
|
08460465 |
Jun 2, 1995 |
|
|
|
08123331 |
Sep 17, 1993 |
|
|
|
Current U.S.
Class: |
424/423 ;
424/608; 514/13.8; 514/13.9; 514/14.8; 514/15.2; 514/19.1; 514/364;
514/509 |
Current CPC
Class: |
A61K 31/21 20130101;
A61K 33/26 20130101; A61L 2300/606 20130101; A61L 29/16 20130101;
A61K 31/4245 20130101; A61L 33/0011 20130101; A61K 31/535 20130101;
A61K 38/58 20130101; A61K 31/295 20130101; A61K 31/195 20130101;
A61K 38/38 20130101; A61L 2300/114 20130101; A61K 38/1709 20130101;
A61K 45/06 20130101; A61K 31/095 20130101; A61K 31/00 20130101;
A61K 47/52 20170801; A61L 27/54 20130101; A61P 7/00 20180101; A61K
31/41 20130101; A61K 33/00 20130101; A61K 38/49 20130101; A61K
38/556 20130101; B82Y 30/00 20130101; A61K 31/04 20130101; A61K
31/275 20130101; A61K 47/62 20170801; A61P 7/02 20180101; A61K
47/6957 20170801; A61L 31/16 20130101; A61P 9/00 20180101; A61L
33/0082 20130101; A61K 38/58 20130101; A61K 2300/00 20130101 |
Class at
Publication: |
424/423 ;
424/608; 514/12; 514/364; 514/509 |
International
Class: |
A61K 038/00; A61K
031/21; A61K 033/00; A61K 031/4245 |
Claims
What is claimed is:
1. A method for preventing or inhibiting platelet deposition or for
alleviating restenosis in a patient in need thereof comprising
administering at least one nitric oxide adduct to a damaged
vascular surface, wherein the damaged vascular surface is the
interior surface of a blood vessel in which damage to the
endothelium or subendothelium, narrowing or stenosis of the vessel
has occurred, and wherein the nitric oxide adduct is a sodium
nitroprusside, a nitrosothiol, a nitrate, a nitrite, a nitrosated
amino acid, a iron-nitrosyl compound, a sydnonimine, or a
furoxan.
2. The method of claim 1, wherein the nitric oxide adduct is
administered via a medical device.
3. The method of claim 1, wherein the medical device comprises a
catheter, a prosthetic heart valve, a synthetic heart valve, a
stent, an intubation tube, an arteriovenous shunt or an artificial
valve.
4. The method of claim 1, wherein the nitric oxide adduct is
administered to the damaged vascular surface by local
administration.
5. The method of claim 1, wherein the nitric oxide adduct is
administered to the damaged vascular surface through the lumen of
an intraarterial or intravenous catheter.
6. The method of claim 2, wherein the nitric oxide adduct is coated
on all or a portion of the medical device.
7. The method of claim 6, wherein the medical device comprises a
polymer matrix and the nitric oxide adduct is bound to or admixed
with the polymer matrix, wherein the polymer is nylon, polyethylene
perthalate or polytetrafluoroethylene.
8. The method of claim 7, wherein the polymer matrix provides for
sustained release of the nitric oxide adduct.
9. The method of claim 1, further comprising administering at least
one anti-thrombogenic compound or a therapeutic agent.
10. The method of claim 9, wherein the anti-thrombogenic compound
is heparin, hirudin, an analog of hirudin, warfarin, aspirin,
indomethacin, dipyridamole, prostacyclin, prostaglandin-E, a
sulfinpyrazone, a phenothiazine, a RGD peptide, a RDG peptide
mimetic, an agent that blocks platelet glycoprotein IIb-IIIa
receptors, ticlopidine or clopidogrel.
11. The method of claim 9, wherein the therapeutic agent is a
monoclonal antibody, a fragment of recombinant human protein, a
viral vector or an anti-sense molecule.
12. The method of claim 1, wherein the nitric oxide adduct delivers
at least one of a nitrosonium ion or a nitroxyl ion under
physiological conditions.
13. The method of claim 1, wherein the nitrosothiol is a
nitrosodithiol or a long carbon chain lipophilic nitrosothiol.
14. The method of claim 1, wherein the nitrate is a
thionitrate.
15. The method of claim 1, wherein the nitrite is a
thionitrite.
16. The method of claim 1, wherein the nitrate is an organic
nitrate.
17. The method of claim 16, wherein the organic nitrate is
nitroglycerin.
18. The method of claim 1, wherein the nitrosated amino acid is a
nitroso-protein.
19. The method of claim 18, wherein the nitroso-protein comprises
at least one thiol group.
20. The method of claim 18, wherein the nitroso-protein is a
nitroso-enzyme, a nitroso-transport protein, a nitroso-heme protein
or a biologically protective nitroso-protein.
21. The method of claim 18, wherein the nitroso-protein is a
S-nitroso-tissue-type plasminogen activator, a S-nitroso-cathepsin,
a S-nitroso-lipoprotein, a S-nitroso-hemoglobin, a
S-nitroso-albumin, a S-nitroso-immunoglobulin or a
S-nitroso-cytokine.
22. The method of claim 18, wherein the nitroso-protein is
polynitrosated.
23. The method of claim 18, wherein the nitroso-protein is
mononitrosated.
24. The method of claim 18, wherein the nitroso-protein is
S-nitroso-albumin.
25. The method of claim 24, wherein the S-nitroso-albumin is
polynitrosated.
26. The method of claim 24, wherein the S-nitroso-albumin is
mononitrosated.
27. The method of claim 24, wherein the S-nitroso-albumin is
S-nitroso-bovine serum albumin.
28. The method of claim 24, wherein the S-nitroso-albumin is
S-nitroso-human serum albumin.
29. A method for treating or preventing a myocardial infarction,
thrombophlebitis, thrombocytopenia or a bleeding disorder in a
patient in need thereof comprising administering at least one
nitric oxide adduct to a damaged vascular surface, wherein the
damaged vascular surface is the interior surface of a blood vessel
in which damage to the endothelium or subendothelium, narrowing or
stenosis of the vessel has occurred, and wherein the nitric oxide
adduct is a sodium nitroprusside, a nitrosothiol, a nitrate, a
nitrite, a nitrosated amino acid, a iron-nitrosyl compound, a
sydnonimine, or a furoxan.
30. The method of claim 29, wherein the nitric oxide adduct is
administered via a medical device.
31. The method of claim 30, wherein the medical device comprises a
catheter, a prosthetic heart valve, a synthetic heart valve, a
stent, an intubation tube, an arteriovenous shunt or an artificial
valve.
32. The method of claim 29, wherein the nitric oxide adduct is
administered to the damaged vascular surface by local
administration.
33. The method of claim 29, wherein the nitric oxide adduct is
administered to the damaged vascular surface through the lumen of
an intraarterial or intravenous catheter.
34. The method of claim 30, wherein the nitric oxide adduct is
coated on all or a portion of the medical device.
35. The method of claim 34, wherein the medical device comprises a
polymer matrix and the nitric oxide adduct is bound to or admixed
with the polymer matrix, wherein the polymer is nylon, polyethylene
perthalate or polytetrafluoroethylene.
36. The method of claim 35, wherein the polymer matrix provides for
sustained release of the nitric oxide adduct.
37. The method of claim 29, further comprising administering at
least one anti-thrombogenic compound or a therapeutic agent.
38. The method of claim 37, wherein the anti-thrombogenic compound
is heparin, hirudin, an analog of hirudin, warfarin, aspirin,
indomethacin, dipyridamole, prostacyclin, prostaglandin-E, a
sulfinpyrazone, a phenothiazine, a RGD peptide, a RDG peptide
mimetic, an agent that blocks platelet glycoprotein IIb-IIIa
receptors, ticlopidine or clopidogrel.
39. The method of claim 37, wherein the therapeutic agent is a
monoclonal antibody, a fragment of recombinant human protein, a
viral vector or an anti-sense molecule.
40. The method of claim 29, wherein the nitric oxide adduct
delivers at least one of a nitrosonium ion or a nitroxyl ion under
physiological conditions.
41. The method of claim 29, wherein the nitrosothiol is a
nitrosodithiol or a long carbon chain lipophilic nitrosothiol.
42. The method of claim 29, wherein the nitrate is a
thionitrate.
43. The method of claim 29, wherein the nitrite is a
thionitrite.
45. The method of claim 29, wherein the nitrate is an organic
nitrate.
45. The method of claim 45, wherein the organic nitrate is
nitroglycerin.
46. The method of claim 29, wherein the nitrosated amino acid is a
nitroso-protein.
47. The method of claim 46, wherein the nitroso-protein comprises
at least one thiol group.
48. The method of claim 46, wherein the nitroso-protein is a
nitroso-enzyme, a nitroso-transport protein, a nitroso-heme protein
or a biologically protective nitroso-protein.
49. The method of claim 46, wherein the nitroso-protein is a
S-nitroso-tissue-type plasminogen activator, a S-nitroso-cathepsin,
a S-nitroso-lipoprotein, a S-nitroso-hemoglobin, a
S-nitroso-albumin, a S-nitroso-immunoglobulin or a
S-nitroso-cytokine.
50. The method of claim 46, wherein the nitroso-protein is
polynitrosated.
51. The method of claim 46, wherein the nitroso-protein is
mononitrosated.
52. The method of claim 46, wherein the nitroso-protein is
S-nitroso-albumin.
53. The method of claim 52, wherein the S-nitroso-albumin is
polynitrosated.
54. The method of claim 52, wherein the S-nitroso-albumin is
mononitrosated.
55. The method of claim 52, wherein the S-nitroso-albumin is
S-nitroso-bovine serum albumin.
56. The method of claim 52, wherein the S-nitroso-albumin is
S-nitroso-human serum albumin.
Description
RELATED APPLICATIONS
[0001] This application is a continuation of U.S. application Ser.
No. 09/621,610 filed Jul. 21, 2000, issued as U.S. Pat. No.
6,471,978, which is a continuation of U.S. application Ser. No.
09/433,550 filed Nov. 4, 1999, issued as U.S. Pat. No. 6,174,539,
which is a continuation of U.S. application Ser. No. 08/460,465
filed Jun. 2, 1995, issued as U.S. Pat. No. 6,087,479, which is a
continuation-in-part of U.S. application Ser. No. 08/123,331 filed
Sep. 17, 1993, abandoned. This application is also related to U.S.
Pat. Nos. 6,255,277 and 6,352,709.
FIELD OF THE INVENTION
[0002] This invention relates to the use of medical devices and to
the treatment of damaged vasculature. More particularly, the
invention relates to the use of medical devices which are inserted
into a patient wherein at least a portion of the device includes a
surface which exposes and delivers a form of nitric oxide to
vascular surfaces with which it comes in contact. Alternatively the
invention relates to the field of preventing the adverse effects
which result from medical procedures which involve the use of such
a medical device and which include administering a source of nitric
oxide to the cite of vasculature contact of such medical
devices.
BACKGROUND OF THE INVENTION
[0003] The vascular endothelium participates in many homeostatic
mechanisms important for the regulation of vascular tone and the
prevention of thrombosis. A primary mediator of these functions is
endothelium-derived relaxing factor (EDRF). First described in 1980
by Furchgott and Zawadzki (Furchgott and Zawadzki, Nature (Lond.).
288:373-376, 1980) EDRF is either nitric oxide (Moncada et al.,
Pharmacol Rev. 43:109-142, 1991.) (NO) or a closely related
No-containing molecule (Myers et al., Nature (Lond.), 345:161-163,
1990).
[0004] Removal of the endothelium is a potent stimulus for
neointimal proliferation, a common mechanism underlying the
restenosis of atherosclerotic vessels after balloon angioplasty.
(Liu et al., Circulation, 79:1374-1387, 1989); (Fems et al.,
Science, 253:1129-1132, 1991). Nitric oxide dilates blood vessels
(Vallance et al., Lancet, 2:997-1000, 1989) inhibits platelet
activation and adhesion (Radomski et al., Br. J Pharmacol,
92:181-187, 1987) and, in vitro, nitric oxide limits the
proliferation of vascular smooth muscle cells (Garg et al., J.
Clin. Invest., 83:1774-1777, 1986). Similarly, in animal models,
suppression of platelet-derived mitogens decreases intimal
proliferation (Fems et al., Science, 253:1129-1132, 1991). The
potential importance of endothelium-derived nitric oxide in the
control of arterial remodeling after injury is further supported by
recent preliminary reports in humans suggesting that systemic NO
donors reduce angiographic-restenosis six months after balloon
angioplasty (The ACCORD Study Investigators, J. Am. Coll. Cardiol.
23:59A. (Abstr.), 1994).
[0005] Biologic thiols react readily with NO (probably as
N.sub.2O.sub.3 or NO) under physiologic conditions to form stable,
biologically active S-nitrosothiol species (Stamler et al., Proc.
Natl. Acad. Sci. U S A., 89:444-448, 1992). S-nitrosothiols exhibit
EDRF-like activity in vitro and in vivo, including vasodilation
(Myers et al., Nature (Lond.), 345:161-163, 1990) and platelet
inhibition via a cyclic 3',5'-guanosine monophosphate
(cGMP)-dependent mechanism (Loscalzo, J. Clin. Invest., 76:703-708,
1985); (Keaney et al., J. Clin. Invest., 91:1582-1589, 1993).
[0006] Over the past two decades, much research effort has been
directed towards the development of medical devices and machines
that are used in a wide variety of clinical settings to maintain
the vital physiological functions of a patient. For example, such
devices as catheters, prosthetic heart valves, arteriovenous shunts
and stents are used extensively in the treatment of cardiac and
other diseases.
[0007] However, platelet deposition on artificial surfaces severely
limits the clinical usefulness of such devices. Forbes et al.,
Brit. Med. Bull. 34(2):201-207, 1978; Sheppeck et al., Blood,
78(3):673-680, 1991. For example, exposure of blood to artificial
surfaces frequently leads to serious thromboembolic complications
in patients with artificial heart valves, synthetic grafts and
other prosthetic devices, and in patients undergoing external
circulation, including cardiopulmonary bypass and hemodialysis.
Salzman, Phil. Trans. R. Soc. Lond., B294:389-398, 1981.
[0008] The normal endothelium which lines blood vessels is uniquely
and completely compatible with blood. Endothelial cells initiate
metabolic processes, like the secretion of prostacyclin and
endothelium-derived relaxing factor (EDRF), which actively
discourage platelet deposition and thrombus formation in vessel
walls. No material has been developed that matches the
blood-compatible surface of the endothelium. In fact, in the
presence of blood and plasma proteins; artificial surfaces are an
ideal setting for platelet deposition (Salzman et al., supra,
1981). Exposure of blood to an artificial surface initiates
reactions that lead to clotting or platelet adhesion and
aggregation. Within seconds of blood contact, the artificial
surface becomes coated with a layer of plasma proteins which serves
as a new surface to which platelets readily adhere, become
activated, and greatly accelerate thrombus formation (Forbes et
al., supra, 1978).
[0009] This creates problems in the use of artificial materials at
the microvascular level, where the ratio of vessel surface area to
blood volume is high (Sheppeck et al., supra). For example,
thromboembolism is still the most serious complication following
prosthetic heart valve implantation, despite changes in design and
materials used. In fact, the incidence of detectable
thromboembolism can be as high as 50%, depending on the valve
design and construction (Forbes et al.). Further, cardiopulmonary
support systems used during cardiac surgery are responsible for
many of the undesirable hemostatic consequences of such surgery
(Bick, Semin. Thromb. Hemost. 3:59-82, 1976). Thrombosis is also a
significant problem in the use of prosthetic blood vessels,
arteriovenous shunts, and intravenous or intraarterial
catheters.
[0010] Conventional methods for preventing thrombus formation on
artificial surfaces have a limited effect on the interaction
between blood and artificial surfaces. For example, in
cardiopulmonary bypass and hemodialysis heparin has little effect,
and the only platelet reactions inhibited by anticoagulants are
those induced by thrombin. In fact, it seems that heparin actually
enhances the aggregation of platelets (Salzman et al., J. Clin.
Invest., 65:64, 1980). To further complicate matters, heparin when
given systemically, can accelerate hemorrhage, already a frequent
complication of cardiac surgery.
[0011] Attempts to inhibit platelet deposit on artificial surfaces
involve systemic administration of aspirin, dipyridamole, and
sulfinpyrazone. While these have some effect in preventing
thromboembolism when given with oral anticoagulants, serious
adverse effects can result. Blood loss is significantly increased
in bypass or hemodialysis patients following administration of
aspirin (Torosian et al., Ann. Intern. Med. 89:325-328, 1978). In
addition, the effect of aspirin and similarly acting drugs is not
promptly reversible, which is essential during cardiopulmonary
bypass. Finally, agents such as aspirin, which depress platelet
function by inhibiting cyclo-oxygenase, may block platelet
aggregation, but they do not prevent the adhesion of platelets to
artificial surfaces (Salzman et al., supra, 1981).
[0012] Despite considerable efforts to develop non-thrombogenic
materials, no synthetic material has been created that is free from
this effect. In addition, the use of anticoagulant and
platelet-inhibiting agents has been less than satisfactory in
preventing adverse consequences resulting from the interaction
between blood and artificial surfaces. Consequently, a significant
need exists for the development of additional methods for
preventing platelet deposition and thrombus formation on artificial
surfaces.
[0013] In the same manner as artificial surfaces, damaged arterial
surfaces within the vascular system are also highly susceptible to
thrombus formation. The normal, undamaged endothelium prevents
thrombus formation by secreting a number of protective substances,
such as endothelium-derived relaxing factor (EDRF), which prevents
blood clotting primarily by inhibiting the activity of platelets.
Disease states such as atherosclerosis and hyperhomocysteinemia
cause damage to the endothelial lining, resulting in vascular
obstruction and a reduction in the substances necessary to inhibit
blood clotting. Thus, abnormal platelet deposition resulting in
thrombosis is much more likely to occur in vessels in which
endothelial damage has occurred. While systemic agents have been
used to prevent coagulation and inhibit platelet function, a need
exists for a means by which a damaged vessel can be treated
directly to prevent thrombus formation.
[0014] Balloon arterial injury results in endothelial denudation
and subsequent regrowth of dysfunctional endothelium (Saville,
Analyst, 83:670-672, 1958) that may contribute to the local smooth
muscle cell proliferation and extracellular matrix production that
result in reocclusion of the arterial lumen.
[0015] Reported work on platelet aggregation has demonstrated the
effect of nitric oxide adducts on the inhibition of
platelet-to-platelet aggregation as a specific stage in clot
formation that relates to their common interaction with each
other.
SUMMARY OF THE INVENTION
[0016] Toward arriving at the present invention, the inventors
hypothesized that local delivery of an EDRF-like species to restore
or replace the deficiency in EDRF noted with dysfunctional
endothelium will modulate the effects of vascular injury and reduce
intimal proliferation following injury. The observations that form
the basis of this invention relate to the active deposition of
platelets on non-platelet tissue beds rather than
platelet-to-platelet aggregation.
[0017] In accordance with an aspect of the present invention, there
is provided a process and product for preventing adverse effects
associated with the use of a medical device in a patient wherein at
least a portion of the device includes a nitric oxide adduct. Such
adverse effects include but are not limited to platelet adhesion
and/or thrombus formation when the medical device is used in a
blood vessel. As known in the art, platelet adhesion and subsequent
platelet activation may result in the blockage of blood vessels
particularly after procedures involving use of a medical device for
removing blockages such as those often referred to as the
phenomenon of restenosis. The medical device can be used elsewhere,
such as for example, in patients having cancer of the
gastrointestinal tract in the Sphincter of Oddi where indwelling
stents (e.g., a Palmaz-Schatz stent, J&J, New Brunswick, N.J.)
are placed to maintain patency of the lumen. They are also used in
patients having cancer of the esophagus to support the airway
opening.
[0018] The medical device or instrument of the invention can be,
for example, a catheter, prosthetic heart valve, synthetic vessel
graft, stent (e.g., Palmaz-Schatz stent), arteriovenous shunt,
artificial heart, intubation tubes, airways and the like.
[0019] As noted above, in this aspect the device is provided a
nitric oxide adduct. Thus, for example, (i) all or a portion of the
medical device may be coated with a nitric oxide adduct, either as
the coating per se or in a coating matrix; (ii) all or a portion of
the medical device may be produced from a material which includes a
nitric oxide adduct, for example, a polymer which has admixed
therewith a nitric oxide adduct or which includes as pendent groups
or grafts one or more of such nitric oxide adducts; or (iii) all or
a portion of the tissue-contracting surfaces of the medical device
may be derivatized with the nitric oxide adduct.
[0020] In the first embodiment of the above aspect, coatings can be
of synthetic or natural matrices, e.g. fibrin or acetate-based
polymers, mixtures of polymers or copolymers, respectively.
Preferably they are bioresorbable or biodegradable matrices. Such
matrices can also provide for metered or sustained release of the
nitric oxide adduct. The device surfaces can be substituted with or
the coating mixture can further include other medicaments, such as
anticoagulants and the like.
[0021] In the next embodiment of this aspect, nitric oxide adducts
are incorporated into the body of a device which is formed of a
biodegradable or bioresorbable material. Thus, intact nitric oxide
adduct is released over a sustained period of the resorption or
degradation of the body of the device.
[0022] In the embodiment relating to the derivatization of an
artificial surface, such as of a medical device or instrument with
a nitric oxide adduct, the artificial surfaces may be composed of
organic materials or a composite of organic and inorganic
materials. Examples of such materials include but are not limited
to synthetic polymers or copolymers containing nitric oxide
adducts, gold or coated metal surfaces upon which a functionalized
monolayer containing the nitric oxide adduct is adsorbed, or
synthetic polymeric materials or proteins which are blended with
nitric oxide adducts.
[0023] Another principal aspect of the invention relates to a
medical device comprising an instrument suitable for introduction
into a patient of which at least a portion comprises a nitric oxide
adduct. As with respect to the above method, (i) all or a portion
of the medical device may be coated with a nitric oxide adduct,
either as the coating per se or in a coating matrix (ii) all or a
portion of the medical device may be produced from a material which
includes a nitric oxide adduct, for example, a polymer which has
admixed therewith a nitric oxide adduct or which includes as
pendent groups or grafts one or more of such nitric oxide adducts;
or (iii) all or a portion of the tissue-contacting surfaces of the
medical device may be derivatized with the nitric oxide adduct.
[0024] Again, the medical device or instrument of the invention can
be, for example, a catheter, prosthetic heart valve, synthetic
vessel graft, stent, arteriovenous shunt, artificial heart,
intubation tube and airways and the like.
[0025] Another principal aspect of the invention relates to a
method for treating a damaged blood vessel surface or other injured
tissue by locally administering a nitric oxide adduct to the site
of the damaged blood vessel. Such damage may result from the use of
a medical device in an invasive procedure. Thus, for example, in
treating vasculature blocked, for example by angioplasty, damage
can result to the blood vessel. Such damage may be treated by use
of a nitric oxide adduct. In addition to repair of the damaged
tissue, such treatment can also be used to prevent and/or alleviate
and/or delay reocclusions, for example. restenosis. Preferably, all
or most of the damaged area is coated with the nitric oxide adduct
per se or in a pharmaceutically acceptable carrier or excipient
which serves as a coating matrix. This coating matrix can be of a
liquid, gel or semisolid consistency. The nitric oxide adduct can
be applied in combination with other therapeutic agents, such as
antithrombogenic agents. The carrier or matrix can be made of or
include agents which provide for metered or sustained release of
the therapeutic agents. Nitric oxide adducts which are preferred
for use in this aspect are mono-or polynitrosylated proteins,
particularly polynitrosated albumin or polymers or aggregates
thereof. The albumin is preferably human or bovine, including
humanized bovine serum albumin.
[0026] The localized, time-related, presence of nitric oxide
adducts administered in a physiologically effective form is
efficacious in diminishing, deterring or preventing vascular damage
after or as a result of instrumental intervention, such as
angioplasty, catheterization or the introduction of a stent (e.g.,
Palmaz-Schatz stent) or other indwelling medical device.
[0027] Local administration of a stable nitric oxide adduct
inhibits neointimal proliferation and platelet deposition following
vascular arterial balloon injury. This strategy for the local
delivery of a long-lived NO adduct is useful for the treatment of
vascular injury following angioplasty.
[0028] Typical nitric oxide adducts include nitroglycerin, sodium
nitroprusside, S-nitroso-proteins, S-nitrosothiols, long
carbon-chain lipophilic S-nitrosothiols, S-nitrosodithiols,
iron-nitrosyl compounds, thionitrates, thionitrites, sydnonimines,
furoxans, organic nitrates, and nitrosated amino acids.
[0029] Particularly preferred is the localized use of
nitroso-proteins, particularly those which do not elicit any
significant immune response. An example of such a nitroso-protein
which does not elicit any significant immune response is a mono- or
polynitrosated albumin. Such nitrosylated albumins, particularly
the polynitrosylated albumins, can be present as polymeric chains
or three dimensional aggregates where the polynitrosylated albumin
is the monomeric unit. The albumin of one monomeric unit can be a
functional subunit of full-length native albumin or can be an
albumin to which has been attached an additional moiety, such as a
polypeptide, which can aid, for example, in localization. The
aggregates are multiple inter adherent monomeric units which can
optionally be linked by disulfide bridges. Additionally devices
which have been substituted or coated with nitroso-protein have the
unique property that they can be dried and stored.
[0030] An additional particularly unique aspect of the invention is
that this contemplates "recharging" the coating that is applied to
a device, such as a catheter or other tubing as considered above,
by infusing a nitric oxide donor to a previously coated surface.
For example, an S-nitroso-protein such as S-nitroso albumin will
lose its potency in vivo as the No group is metabolized, leaving
underivatized albumin. However, it has been recognized by the
inventors that the surface coating can be "recharged" by infusing
an NO donor such as nitroprusside. This principal is demonstrated
by the experiments reported in Example 2 in which nitroprusside is
mixed with albumin engendering subsequent protection against
platelet deposition.
[0031] Another aspect of the invention is related to the
derivatization of an artificial surface with a nitric oxide adduct
for preventing the deposit of platelets and for preventing thrombus
formation on the artificial surface. The artificial surfaces may be
composed of organic materials or a composite of organic and
inorganic materials. Examples of such materials include but are not
limited to synthetic polymers or copolymers containing nitric oxide
adducts, gold or gold coated metal surfaces upon which a
functionalized monolayer containing the nitric oxide add It is
adsorbed, or synthetic polymeric materials or proteins which are
blended with nitric oxide adducts.
[0032] The invention also relates to a method and product for
administering a nitric oxide adduct in combination with one or more
anti-thrombogenic agents. Such agents include heparin, warfarin,
hirudin and its analogs, aspirin, indomethacin, dipyridamole,
prostacyclin, prostaglandin E.sub.1, sulfinpyrazone, phenothiazines
(such as chlorpromazine or trifluperazine) RGD
(arginine-glycine-aspartic acid) peptide or RGD peptide mimetics,
(See Nicholson et al., Thromb. Res., 62:567-578, 1991), agents that
block platelet glycoprotein IIb-IIIa receptors (such as C-7E3),
ticlopidine or the thienopyridine known as clopidogrel.
[0033] Other therapeutic agents can also be included in the coating
or linked to reactive sites in or on the body of the device.
Examples of these include monoclonal antibodies directed towards
certain epitopes/ligands such as platelet glycoprotein IIb/IIIa
receptor or cell adhesion molecules such as the CD-18 complex of
the integrins or PECAM-1; fragments of recombinant human proteins
eg, albumin; pegylated proteins; anti-sense molecules; viral
vectors designed as vehicles to deliver certain genes or nucleoside
targeting drugs.
BRIEF DESCRIPTION OF THE FIGURES
[0034] The invention will now be further described by reference to
a brief description of each of the Figures, but in no way are a
limitation of the scope of the invention.
[0035] FIG. 1A is a synthetic scheme for the preparation of a
nitrosothiol incorporated on to the .epsilon.-amino group of a
copolymer comprised of poly-L-lactic acid-co-lysine.
[0036] FIG. 1B is a synthetic scheme for the preparation of a
nitrosothiol incorporated on to the c-amino group of a copolymer
comprised of poly-L-lactic acid-co-L-lysine.
[0037] FIG. 2 is a synthetic scheme for the preparation of a
nitrosothiol incorporated onto an amino derivatized self-assembled
monolayer (SAMS) adsorbed to a gold surface.
[0038] FIG. 3 is a plot demonstrating ([.sup.125I]-labeled
S-nitroso-albumin ([.sup.125I]-S-NO-BSA) binding to injured rabbit
femoral artery as a function of the method of delivery. Rabbit
femoral arteries were isolated and balloon-injured as described in
Example 1 and [.sup.125I]-S-NO-BSA applied either directly into the
injured artery (local) or injected intraarterially via the opposite
femoral artery (systemic). [.sup.125I]-S-NO-BSA binding was
determined by quantification of radioactivity after flow was
reestablished for a period of 15 minutes. Non-specific
[.sup.125I]-S-NO-BSA binding (sham) was determined from uninjured
carotid artery harvested simultaneously with femoral arteries. Data
are presented as mean+/-SEM per gram of wet tissue weight, and are
derived from four animals. *P<0.0.029, local vs. systemic
delivery and +/+P<0.05, systemic injured vs. sham.
[0039] FIG. 4 is a plot demonstrating the effect of polythiolated
S-nitroso-albumin (pS-NO-BSA) and polythiolated albumin (pS-BSA) on
[.sup.111In]-labeled platelet binding to injured rabbit femoral
arteries. Femoral arteries were isolated and balloon injured as
described in Example 1. During paired local administration of
polythiolated S-nitroso-albumin and polythiolated albumin,
[.sup.111In]-labeled platelets were administered intravenously and
allowed to circulate after flow was reestablished in the treated
arteries. ([.sup.111In]-labeled platelet binding was determined by
quantification of radioactivity after flow was re-established for a
period of 15 minutes. Non-specific [.sup.111In]-labeled platelet
binding (Uninjured Carotid Artery) was determined from uninjured
carotid artery harvested with femoral arteries. Data are presented
as mean+/-SEM per gram of wet tissue weight and are derived from
six animals. *P<0.05, PS-BSA vs. pS-NO-BSA.
[0040] FIGS. 5A-5B are plots demonstrating the effect of
polythiolated S-nitroso-albumin (pS-NO-BSA) and polythiolated
albumin (pS-BSA) on neointimal proliferation 14 days after balloon
injury of rabbit femoral artery. Femoral arteries were isolated and
balloon injured as described below. pS-BSA or pS-NO-BSA were
applied in a paired fashion directly into the arterial lumen for 15
minutes and then blood flow was re-established. After 14 days,
arteries were harvested, perfusion-fixed, stained, and subjected to
morphometric analysis of intimal and medial areas. Neointimal
proliferation is reported as the absolute neointimal area in FIG.
5A and as a ratio of neointimal/media in FIG. 5B in 4-6 segments
from each artery. Data are expressed as mean+/-SEM and are derived
from 15 vessels in the BSA and S-NO-BSA groups, 11 vessels in the
PS-BSA group, 7 vessels in the PS-NO-BSA and SHAM groups, and 5 in
the SNP group. *P<0.05, pS-NO-BSA vs. PS-BSA. +/+P<0.05
Sodium nitroprusside vs. pS-BSA for both FIGS. 5A and 5B.
[0041] FIGS. 6A-6B are plots demonstrating the relationship between
neointimal proliferation and the quantity of displaceable No in
preparations of S-nitrosylated albumin. Femoral arteries were
isolated and balloon injured as described with reference to FIG. 5.
Vessels were exposed to different preparations of S-nitrosylated
albumin with different displaceable NO contents. After 14 days
vessels were harvested and analyzed as described in FIG. 5. Data
are expressed as mean+/-SEM and are derived from 7-15 animals in
each group. P<0.001 for trend.
[0042] FIG. 7 is a plot demonstrating the effect of polythiolated
S-nitroso-albumin (pS-NO-BSA)- and polythiolated albumin
(pS-BSA)-treated vessels on platelet cyclic 5'-3' guanosine
monophosphate (cGMP). Rabbit femoral arteries were isolated and
balloon-injured as described with reference to FIG. 4. After paired
local administration of polythiolated S-nitroso-albumin and
polythiolated albumin for 15 minutes, the vessels ere harvested and
divided into 2 mm rings. The rings were then immersed in 100 .mu.l
of latelet-rich plasma containing 10 .mu.M
3-isobutyl-1-methylxanthine and were incubated for 1 minute
ex-vivo. An equal volume of ice-cold 10% trichloroacetic acid was
added to each aliquot and the sample vortexed. Platelet cGMP assay
was then performed as described in "Methods." Data are expressed as
mean+/-SEM. *P<0.05.
[0043] FIG. 8 is a flow chart illustrating the protocol of Example
4 which measured the effect on balloon-induced injury of pS-NO-BSA
or pS-BSA in porcine coronary artery.
[0044] FIG. 9 is a histogram which illustrates the diameter (mm) of
the neointimal lumen of 14 normocholesterolemic pigs were subjected
to a balloon angioplasty which induced injury of the right coronary
artery. Thereafter, they received 1.5 .mu.M pS-NO-BSA or pS-BSA as
a control.
[0045] FIG. 10 is a histogram which illustrates a degree of
coronary stenosis observed at four weeks after angioplasty in pigs
which received 1.5 .mu.M pS-NO-BSA or pS-BSA as a control.
[0046] FIG. 11 is a histogram which illustrates the extent of
coronary spasm induced distal the site of injury as compared to the
pre-existing base line in pigs which received 1.5 .mu.M pS-NO-BSA
or pS-BSA as a control.
[0047] FIG. 12 is a histogram which illustrates the inner-diameter
of-the lumen of the right coronary artery of pigs four weeks after
they received 1.5 .mu.M pS-NO-BSA or pS-BSA as a control.
DETAILED DESCRIPTION OF THE INVENTION
[0048] The invention will now be described in more detail with
respect to numerous embodiments and examples in support
thereof.
[0049] The term "artificial surface" refers to any synthetic
material contained in a device or apparatus that is in contact with
blood, blood products or components, vasculature, or other
tissue.
[0050] The term "platelet adhesion" refers to the contact of a
platelet with a foreign surface, e.g. collagen, artificial surface
or device.
[0051] The term "platelet aggregation" refers to the adhesion of
one or more platelets to each other. Platelet aggregation is
commonly referred to in the context of generalized atherosclerosis,
not with respect to platelet adhesion on vasculature damaged as a
result of physical insult during a medical procedure.
[0052] The term "restenosis" refers to the recurrent narrowing of a
blood vessel, usually several months after an injurious insult and
as a result of neointimal proliferation.
[0053] The term "passivation" refers to the coating of a surface
which thereby renders the surface non-reactive.
[0054] The term "reendothelialization" refers to the proliferation,
migration and spreading of endothelial cells over a surface area
which is denuded of endothelial cells, e.g., the surface of a
damaged blood vessel.
[0055] The term "platelet activation" refers either to the change
in conformation (shape) of a cell, expression of cell surface
proteins (e.g., the IIb/IIa receptor complex, loss of GPIb surface
protein), secretion of platelet derived factors (e.g., serotonin,
growth factors).
[0056] The term "lower alkyl" as used herein refers to a branched
or straight chain alkyl groups comprising one to ten carbon atoms,
including methyl, ethyl, propyl, isopropyl, n-butyl, t-butyl,
neopentyl and the like.
[0057] The term "alkoxy" as used herein refers to R.sub.20O--,
wherein R.sub.20 is lower alkyl as defined above. Representative
examples of alkoxy groups include methoxy, ethoxy, t-butoxy and the
like.
[0058] The term "alkoxyalkyl" as used herein refers to an alkoxy
group as previously defined appended to an alkyl group as
previously defined. Examples of alkoxyalkyl include, but are not
limited to, methoxymethyl, methoxyethy, isopropoxymethyl and the
like.
[0059] The term "amino" as used herein refers to --NH.sub.2.
[0060] The term "dialkylamino" as used herein refers to
R.sub.22R.sub.23N-- wherein R.sub.22 and R.sub.23 are independently
selected from lower alkyl, for example dimethylamino, diethylamino,
methyl propylamino and the like.
[0061] The term "nitro" as used herein refers to the group
--NO.sub.2.
[0062] The term "nitroso" as used herein refers to the group
--NO.
[0063] The term "hydroxyl" or "hydroxy" as used herein refers to
the group --OH.
[0064] The term "cyano" as used herein refers to the group
--CN.
[0065] The term "carbomoyl" as used herein refers to
H.sub.2N--C(O)O--.
[0066] The term N,N-dialkylcarbomoyl as used herein refers to
R.sub.22R.sub.23N--C(O)O-- wherein R.sub.22 and R.sub.23 are
independently selected from lower alkyl, for example dimethylamino,
diethylamino, methyl propylamino, and the like.
[0067] The term N-alkylcarbamoyl as used herein refers to
R.sub.22HN--C(O)O-- wherein R.sub.22 is selected from lower alkyl,
for example methylamino, ethylamino, propylamino, and the like.
[0068] The term "aryl" as used herein refers to a mono- or bicyclic
carbocyclic ring system having one or two aromatic rings including,
but not limited to, phenyl, naphthyl, tetrahydronaphthyl, indanyl,
indenyl, and the like. Aryl groups (including bicyclic aryl groups)
can be unsubstituted or substituted with one, two or three
substituents independently selected from lower alkyl, haloalkyl,
alkoxy, amino, alkylamino, dialkylamino, hydroxy, halo, and nitro.
In addition, substituted aryl groups include tetrafluorophenyl and
pentafluorophenyl.
[0069] The term "arylthio" as used herein refers to R.sub.24S--
wherein R.sub.24 is selected from aryl.
[0070] The term "alkanoyl" as used herein refers to R.sub.22C(O)--
wherein R.sub.22 is selected from lower alkyl.
[0071] The term "carboxyl" as used herein refers to --COOH.
[0072] The term "guanidino" as used herein refers to
H.sub.2N--C(.dbd.NH)NH--.
[0073] The term "arylalkyl" as used herein refers to a lower alkyl
radical to which is appended an aryl group. Representative
arylalkyl groups include benzyl, phenyl, hydroxybenzyl,
fluorobenzyl, fluorophenylethyl and the like.
[0074] The term "cycloalkyl" as used herein refers to an alicyclic
group comprising from 3 to 7 carbon atoms including, but not
limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and
the like.
[0075] The term "halogen" or "halo" as used herein refers to I, Br,
Cl, or F. The term "haloalkyl" as used herein refers to a lower
alkyl radical, as defined above, bearing at least one halogen
substituent, for example, chloromethyl, fluoroethyl or
trifluoromethyl and the like.
[0076] The term "heteroaryl" as used herein refers to a
mono-bicyclic ring system containing one or two aromatic rings and
containing at least one nitrogen, oxygen, or sulfur in an aromatic
ring. Heteroaryl groups (including bicyclic heteroaryl groups) can
be unsubstituted or substituted with one, two, or three
substituents independently selected from lower alkyl, haloalkyl,
alkoxy, amino, alkylamino, dialkylamino, hydroxy, halo and nitro.
Examples of heteroaryl groups include not limited to pyridine,
pyrazine, pyrimidine, pyridazine, pyrazole, triazole, thiazole,
isothiazole, benzothiazole, benzoxazole, thiadiazole, oxazole,
pyrrole, imidazole, and isoxazole.
[0077] The term "heterocyclic ring" refers to any 3-, 4-, 5-, 6-,
or 7-membered nonaromatic ring containing at least one nitrogen
atom which is bonded to an atom which is not part of the
heterocyclic ring. In addition, the heterocyclic ring may also
contain a one additional hetero atom which may be nitrogen, oxygen,
or sulfur.
[0078] Compounds of the invention which have one or more asymmetric
carbon atoms may exist as the optically pure enantiomers, pure
diastereomers, mixtures of enantiomers, mixtures of diastereomers,
racemic mixtures of enantiomers, diastereomeric racemates or
mixtures of diastereomeric racemates. It is to be understood that
the present invention anticipates and includes within its
scope.
[0079] As mentioned above, the medical device or instrument may be
made, such that at least in those portions of it which come into
contact with blood, blood components or products, or vascular
tissue, include a nitric oxide adduct. The nitric oxide adduct can
directly or indirectly be linked to a synthetic material from which
all or a portion of the device is formed. As representative
examples, there may be mentioned: nylon, polyethylene perthalate
(Dacron), polytetrafluoroethylene (Gortex).
[0080] In another embodiment mentioned above, the nitric oxide
adduct can be incorporated into a natural or synthetic matrix which
is then used to coat those same contact surfaces of the device. The
matrix can be a liquid into which the nitric oxide adduct has been
mixed, which is then coated onto the contact surfaces of the
medical device or instrument and then allowed to "set", dry,
polymerize or otherwise become solid or semisolid. Examples of such
matrix materials include gel-forming materials such as are commonly
used including hydrogels and starch-based semi-solid emulsions and
dispersions.
[0081] The materials can also be polymers or mixtures of polymers
such as polylactic acid/polylysine copolymer. Alternatively, the
matrix can be a natural or synthetic fibrous matrix which is
impregnated with a liquid containing the nitric oxide adducts
either before or after being applied to the artificial contact
surface. Examples of such natural fibrous matrix materials
primarily include filter paper. Examples of such synthetic fibrous
matrix materials include three-dimensional lattices of synthetic
polymers and copolymers.
[0082] The matrix can also be a material such as nylon or plastic,
such as polystyrene, that is directly or indirectly, i.e., through
a linking group, derivatized with the nitric oxide adduct.
[0083] As mentioned above the nitric oxide adduct is specifically
intended to be delivered locally at the site of contact of the
device or instrument with the blood, blood product or component, or
vasculature, but need not be physically associated with the device
or instrument. For example, the nitric oxide adduct can be
separately administered in a physiologically available form as a
pharmaceutical preparation in a pharmaceutically acceptable
carrier, such as are described in more detail below. This can be
done by administration during or shortly before the contact or
intervention. Where the device is, for example, a catheter, such as
a cardiac catheter, the nitric oxide adduct preparation can be
administered by injection into the lumen of the catheter.
[0084] Compounds contemplated for use in the invention are nitric
oxide and compounds that release nitric oxide or otherwise directly
or indirectly deliver or transfer nitric oxide to a site of its
activity, such as on a cell membrane, in vivo. As used here, the
term "nitric oxide" encompasses uncharged nitric oxide (NO.) and
charged nitric oxide species, particularly including nitrosonium
ion (NO.sup.+) and nitroxyl ion (NO.sup.-). The reactive form of
nitric oxide can be provided by gaseous nitric oxide. The nitric
oxide releasing delivering or transferring. Compounds, having the
structure X--NO wherein X is a nitric oxide releasing, delivering
or transferring moiety, include any and all such compounds which
provide nitric oxide to its intended site of action in a form
active for their intended purpose. As used here, the term "nitric
oxide adducts" encompasses any of such nitric oxide releasing,
delivering or transferring compounds, including, for example,
S-nitrosothiols, S-nitroso amino acids, S-nitroso-polypeptides, and
nitrosoamines. It is contemplated that any or all of these "nitric
oxide adducts" can be mono- or polynitrosylated at a variety of
naturally susceptible or artificially provided binding sites for
nitric oxide.
[0085] One group of such nitric oxide adducts is the
S-nitrosothiols, which are compounds that include at least one
--S--NO group. Such compounds include S-nitroso-polypeptides (the
term "polypeptide" includes proteins and also polyamino acids that
do not possess an ascertained biological function, and derivatives
thereof); S-nitrosylated amino acids(including natural and
synthetic amino acids and their stereoisomers and racemic mixtures
and derivatives thereof); S-nitrosated sugars,
S-nitrosated-modified and unmodified oligonucleotides (preferably
of at least 5, and more particularly 5-200, nucleotides); and an
S-nitrosated hydrocarbon where the hydrocarbon can be a branched or
unbranched, and saturated or unsaturated aliphatic hydrocarbon, or
an aromatic hydrocarbon; S-nitroso hydrocarbons having one or more
substituent groups in addition to the S-nitroso group; and
heterocyclic compounds. S-nitrosothiols and the methods for
preparing them are described in U.S. patent application Ser. No.
07/943,834, filed Sep. 14, 1992, Oae et al., Org. Prep. Proc. Int.,
15(3):165-198, 1983; Loscalzo et al., J. Pharmacol. Exp. Ther.,
249(3):726729, 1989, and Kowaluk et al., J. Pharmacol. E. Ther.,
256:1256-1264, 1990, all of which are incorporated in their
entirety by reference.
[0086] One particularly preferred embodiment of this aspect relates
to S-nitroso amino acids where the nitroso group is linked to a
sulfur group of a sulfur-containing amino acid or derivative
thereof. For example, such compounds include the following:
S-nitroso-N-acetylcysteine, S-nitroso-captopril,
S-nitroso-homocysteine, S-nitroso-cysteine and
S-nitroso-glutathione.
[0087] Suitable S-nitrosylated proteins include thiol-containing
proteins(where the NO group is attached to one or more sulfur group
on an amino acid or amino acid derivative thereof) from various
functional classes including enzymes, such as tissue-type
plasminogen activator(TPA) and cathepsin B; transport proteins,
such as lipoproteins, heme proteins such as hemoglobin and serum
albumin; and biologically protective proteins, such as the
immunoglobulins and the cytokines. Such nitrosylated proteins are
described in PCT Publ. Applic. No. WO 93/09806, published May 27,
1993. Examples include polynitrosylated albumin where multiple
thiol or other nucleophilic centers in the protein are
modified.
[0088] Further examples of suitable S-nitrosothiols include those
having the structures: (i) CH.sub.3(CH.sub.2).sub.xSNO, wherein x
equals 2 to 20; (ii) HS(CH.sub.2).sub.xSNO, wherein x equals 2 to
20; and (iii) ONS(CH.sub.2).sub.xY, wherein x equals 2 to 20 and Y
is selected from the group consisting of halo, alkoxy, cyano,
carboxamido, cycloalkyl, arylalkoxy, lower alkylsulfinyl, arylthio,
alkylamino, dialkylamino, hydroxy, carbamoyl, N-alkylcarbamoyl,
N,N-dialkylcarbamoyl, amino, hydroxyl, carboxyl, hydrogen, nitro
and aryl.
[0089] Other suitable S-nitrosothiols that are
S-nitroso-angiotensin converting enzyme inhibitors (hereinafter
referred to as S-nitroso-ACE inhibitors) are described in Loscalzo,
U.S. Pat. No. 5,002,964 (1991) and Loscalzo et al., U.S. Pat. No.
5,025,001 (1991) both of which are incorporated in their entirety
by reference. Examples of such S-nitroso-ACE inhibitors include
compounds having structure (1): 1
[0090] wherein
[0091] R is hydroxy, NH.sub.2, NHR.sup.4, NR.sup.4R.sup.5, or lower
alkoxy, wherein R.sup.4 and R.sup.5 are lower alkyl, or aryl, or
arylalkyl;
[0092] R.sub.1 is hydrogen, lower alkyl, arylalkyl, amino,
guanidino, NHR.sup.6, NHR.sup.6R.sup.7, wherein R.sup.6 and R.sup.7
are methyl or alkanoyl;
[0093] R.sub.2 is hydrogen, hydroxy, C.sub.1-C.sub.4 alkoxy,
phenoxy, or lower alkyl;
[0094] R.sub.3 is hydrogen, lower alkyl or arylalkyl;
[0095] m is 1 to 3; and
[0096] n is 0 to 2.
[0097] Other suitable S-nitroso-ACE inhibitors include
N-acetyl-S-nitroso-D-cysteinyl-L-proline,
N-acetyl-S-nitroso-D,L-cysteiny- l-L-proline,
1-[4-amino-2-(S-nitroso)mercaptomethyl butanoyl]-L-proline,
1-[2-hexanoyl]-L-proline,
1-[5-guanidino-2-(S-nitroso)mercaptomethyl-pent- anoyl]-L-proline,
1-[5-amino-2-(S-nitroso) mercaptomethyl-pentanoyl]-4-hyd-
roxy-L-proline,
1-[5-guanidino-2-(S-nitroso)mercaptomethyl-pentanoyl]-4-hy-
droxy-L-proline,
1-[2-aminomethyl-3(S-nitroso)-mercaptomethyl-pentanoyl-L-- proline,
and S-nitroso-L-cysteinyl-L-proline.
[0098] Additional suitable S-nitroso-ACE inhibitors include those
having structures (2-3): 2
[0099] wherein
[0100] X is oxygen or sulfur;
[0101] --A.sub.1, --A.sub.2-- is CH--NH or --C.dbd.N--;
[0102] A is ON--S(R.sub.3)--CH.sub.2--CH--C(.dbd.O);
[0103] R is selected from hydrogen, lower alkyl, arylalkyl, and
salt forming ion;
[0104] R.sub.4 and R.sub.5 are independently selected from
hydrogen, alkyl, lower alkoxy, halo substituted lower alkyl, nitro,
and SO.sub.2NH.sub.2;
[0105] Z is --C(.dbd.O)-- or --S(O.sub.2)--
[0106] R.sub.6 is hydogen, lower alkyl, halo substituted lower
alkyl, hydroxy substituted lower alkyl,
--(CH..sub.2).sub.q--N(lower alkyl).sub.2 or
--(CH.sub.2).sub.q--NH.sub.2 and q is one, two, three or four; and
3
[0107] wherein R.sub.7 is hydrogen, lower alkyl, alkoxy, halogen or
hydroxy and g is as defined above.
[0108] Additional suitable compounds include those having
structures (4-11): 4
[0109] The S-nitroso-ACE inhibitors can be prepared by various
methods of synthesis. In general, the thiol precursor is prepared
first, then converted to the S-nitrosothiol derivative by
nitrosation of the thiol group with NaNO.sub.2 under acidic
conditions (pH=1 to 5) which yields the S-nitroso derivative. Acids
which may be used for this purpose include aqueous sulfuric, acetic
and hydrochloric acids. Thiol precursors are prepared as described
in the following: U.S. Pat. No. 4,046,889 (1977); U.S. Pat. Nos.
4,052,511; 4,053,651; 4,113,751, 4,154,840, 4129,571 (1978), and
U.S. Pat. No. 4,154,960 (1979) to Ondetti et al.; U.S. Pat. No.
4,626,545 (1986) to Taub; and U.S. Pat. No. 4,692,458 (1987) and
U.S. Pat. No. 4,692,459 (1987) to Ryan et al., Quadro, U.S. Pat.
No. 4,447,419 (1984); Haugwitz et al.; U.S. Pat. No. 4,681,886
(1987), Bush et al., U.S. Pat. No. 4,568,675 (1986), Bennion et
al., U.S. Pat. No. 4,748,160 (1988), Portlock, U.S. Pat. No.
4,461,896 (1984), Hoefle et al., European Patent Application
Publication No. 0 088 341 (1983), Huange et al., U.S. Pat. No.
4,585,758 (1986), European Patent application Publication No. 0 237
239, European Patent application Publication No. 0 174 162,
published in 1986, European Patent application Publication No. 0
257 485, published in 1988, all of which are incorporated by
reference herein.
[0110] Another group of such NO adducts are compounds that include
at least one --O-- NO group. Such compounds include
O-nitroso-polypeptides (the term "polypeptide" includes proteins
and also polyamino acids that do not possess an ascertained
biological function, and derivatives thereof); O-nitrosylated amino
acids (including natural and synthetic amino acids and their
stereoisomers and racemic mixtures and derivatives thereof);
O-nitrosated sugars; O-nitrosated-modified and unmodified
oligonucleotides (preferably of at least 5, and more particularly
5-200, nucleotides); and an O-nitrosated hydrocarbon where the
hydrocarbon can be a branched or unbranched, saturated or
unsaturated aliphatic hydrocarbon, or an aromatic hydrocarbon;
O-nitroso hydrocarbons having one or more substituent groups in
addition to the O-nitroso group; and heterocyclic compounds.
[0111] Another group of such NO adducts is the nitrites which have
an --O-NO group wherein R is a protein, polypeptide, amino acid,
branched or unbranched and saturated or unsaturated alkyl, aryl or
a heterocyclic. A preferred example is the nitrosylated form of
isosorbide. Compounds in this group form S-nitrosothiol
intermediates in vivo in the recipient human or other animal to be
treated and can therefore include any structurally analogous
precursor R--O--NO of the S-nitrosothiols described above.
[0112] Another group of such NO adducts is the N-nitrosoamines,
which are compounds that include at least one --N--NO group. Such
compounds include N-nitroso-polypeptides (the term "polypeptide"
includes proteins and also polyamino acids that do not possess an
ascertained biological function, and derivatives thereof);
N-nitrosylated amino acids (including natural and synthetic amino
acids and their stereoisomers and racemic mixtures); N-nitrosated
sugars; N-nitrosated-modified and unmodified oligonucleotides
(preferably of at least 5, and more particularly 5-200,
nucleotides); and an N-nitrosated hydrocarbon where the hydrocarbon
can be a branched or unbranched, and saturated or unsaturated
aliphatic hydrocarbon, or an aromatic hydrocarbon; N-nitroso
hydrocarbons having one or more substituent groups in addition to
the N-nitroso group; and heterocyclic compounds.
[0113] Another group of such NO adducts is the C-nitroso compounds
that include at least one --C--NO group. Such compounds include
C-nitroso-polypeptides (the term "polypeptide" includes proteins
and also polyamino acids that do not possess an ascertained
biological function, and derivatives thereof); C-nitrosylated amino
acids (including natural and synthetic amino acids and their
stereoisomers and racemic mixtures); C-nitrosated sugars;
C-nitrosated-modified and unmodified oligonucleotides (preferably
of at least 5, and more particularly 5-200, nucleotides); and a
C-nitrosated hydrocarbon where the hydrocarbon can be a branched or
unbranched, and saturated or unsaturated aliphatic hydrocarbon, or
an aromatic hydrocarbon; C-nitroso hydrocarbons having one or more
substituent groups in addition to the C-nitroso group; and
heterocyclic compounds.
[0114] Another group of such NO adducts is the nitrates which have
at least one --O--NO.sub.2 group. Such compounds include
polypeptides (the term "polypeptide" includes proteins and also
polyamino acids that do not possess an ascertained biological
function, and derivatives thereof); amino acids (including natural
and synthetic amino acids and their stereoisomers and racemic
mixtures and derivatives thereof); sugars; modified and unmodified
oligonucleotides (preferably of at least 5, and more particularly
5-200, nucleotides); and a hydrocarbon where the hydrocarbon can be
a branched or unbranched, and saturated or unsaturated aliphatic
hydrocarbon, or an aromatic hydrocarbon; hydrocarbons having one or
more substituent groups; and heterocyclic compounds. A preferred
example is nitroglycerin.
[0115] Another group of such NO adducts is the nitroso-metal
compounds which have the structure (R).sub.n--A--M--(NO).sub.x. R
includes polypeptides(the term "polypeptide" includes proteins and
also polyamino acids that do not possess an ascertained biological
function, and derivatives thereof); amino acids (including natural
and synthetic amino acids and their stereoisomers and racemic
mixtures and derivatives thereof); sugars; modified and unmodified
oligonucleotides (preferably of at least 5, and more particularly
5-200, nucleotides); and a hydrocarbon where the hydrocarbon can be
a branched or unbranched, and saturated or unsaturated aliphatic
hydrocarbon, or an aromatic hydrocarbon; hydrocarbons having one or
more substituent groups in addition to the A-nitroso group; and
heterocyclic compounds. A is S, O, or N, n and x are each integers
independently selected from 1, 2 and 3, and M is a metal,
preferably a transition metal. Preferred metals include iron,
copper, manganese, cobalt, selenium and lithium. Also contemplated
are N-nitrosylated metal centers such as nitroprusside.
[0116] Another group of such NO adducts is the
N-oxo-N-nitrosoamines which have an R--N(O.sup.-M.sup.+)--NO group
or an R--NO--NO-group. R includes polypeptides (the term
"polypeptide" includes proteins and also polyamino acids that do
not possess an ascertained biological function, and derivatives
thereof); amino acids(including natural and synthetic amino acids
and their stereoisomers and racemic mixtures and derivatives
thereof); sugars; modified and unmodified oligonucleotides
(preferably of at least 5, and more particularly 5-200,
nucleotides); and a hydrocarbon where the hydrocarbon can be a
branched or unbranched, and saturated or unsaturated aliphatic
hydrocarbon, or an aromatic hydrocarbon; hydrocarbons having one or
more substituent groups; and heterocyclic compounds. R is
preferably a nucleophilic (basic) moiety. M+ is a metal cation,
such as, for example, a Group I metal cation.
[0117] Another group of such NO adducts is the thionitrates which
have the structure R--(S).sub.x--NO wherein x is an integer of at
least 2. R is as described above for the S-nitrosothiols. Preferred
are the dithiols wherein x is 2. Particularly preferred are those
compounds where R is a polypeptide or hydrocarbon and a pair or
pairs of thiols are sufficiently structurally proximate, i.e.
vicinal, that the pair of thiols will be reduced to a disulfide.
Those compounds which form disulfide species release nitroxyl ion
(NO) and uncharged nitric oxide (NO.). Those compounds where the
thiol groups are not sufficiently close to form disulfide bridges
generally only provide nitric oxide as the NO form not as the
uncharged NO. form.
[0118] Coating of a surface of a medical device with the nitric
oxide adduct comprises contacting the surface with the adduct so as
to cause the surface to be coated with the particular adduct.
Coating of the artificial surface may be accomplished using the
methods described in Example 1, infra, or other standard methods
well known to those of ordinary skill in the art. For example,
coating a surface with nitric oxide adducts can be achieved by
bathing the artificial surface, either by itself or within a
device, in a solution containing the nitric oxide adduct. In
addition, synthetic nitric oxide adducts may be coated onto an
artificial surface by a variety of chemical techniques which are
well known in the art. Such techniques include attaching the adduct
to a nucleophilic center, metal, epoxide, lactone, an alpha- or
beta-saturated carbon chain, alkyl halide, carbonyl group, or
Schiff base, by way of the free thiol.
[0119] In order to optimize the coating techniques further,
standard methods may be used to determine the amount of platelet
deposition on a sample of the treated artificial surface. Such
methods include the use of .sup.51Cr-labeled platelets or
Indium.sup.111-labeled platelets. Other well known techniques for
evaluating platelet deposition on artificial surfaces are described
in Forbes et al. (1978), and Salzman et al. (1981).
[0120] It is also contemplated that artificial surfaces will vary
depending on the nature of the surface, and such characteristics as
contour, crystallinity, hydrophobicity, hydrophilicity, capacity
for hydrogen bonding, and flexibility of the molecular backbone and
polymers. Therefore, using routine methods, one of ordinary skill
will be able to customize the coating technique by adjusting such
parameters as the amount of adduct, length of treatment,
temperature, diluents, and storage conditions, in order to provide
optimal coating of each particular type of surface.
[0121] After the device or artificial material has been coated with
the nitric oxide adduct, it will be suitable for its intended use,
for example, implantation as a heart valve, insertion as a
catheter, or for cardiopulmonary oxygenation or hemodialysis. The
coated device or artificial surface will be suitable for use in
conjunction with an animal, preferably mammals, including
humans.
[0122] Another embodiment of a nitric oxide adduct pertains to the
derivatization of synthetically derived polymeric materials. Nitric
oxide adducts of the formula IA wherein b is an integer from 270 to
500, c is an integer of 1 to 2, d is an integer from 1 to 6, E is a
covalent bond, S, N, O, or C--N--C(O)--R.sup.0, in which R.sup.0 is
H. lower alkyl, cycloalkyl, aryl, heteroaryl, or heterocyclic ring
system may be prepared according to the reaction scheme depicted in
FIG. 7A, in which the biodegradable poly L-lactic
acid/poly-L-lysine copolymer prepared as described by Berrera et
al., J. Am. Chem. Soc., 115:11010, 1993) is representative of the
synthetic polymeric materials defined above. The primary amino
groups of the compound of formula 13 are reacted with a compound of
formula 14, wherein T is an activated carbonyl-containing
substituent selected from a group consisting of a mixed anhydride,
a thioester, an acid chloride, an isocyanate, or a chloroformate,
P.sup.1 is a sulfur protecting group, and E and d are defined as
above to afford a compound of the formula 15 wherein b, c, E, d,
and P.sup.1 are defined as above. A variety of sulfur protecting
groups which are compatible with this process along with methods
for their incorporation and removal are described in T. H. Greene
and P. G. M. Wuts, Protective Groups in Organic Synthesis, 2nd
edition, John Wiley & Sons, New York, 1991. The sulfur
protecting groups in the compound of the formula 15 are removed to
afford the compound of the formula 16 and the thiol moieties are
nitrosated to afford a compound of the formula IA using a suitable
mild nitrosating agent such as nitrosyl chloride or nitrosonium
tetrafluoroborate in an inert organic solvent or mixture of inert
solvents such as methylene chloride, chloroform, dimethyforamide
(DMF), dimethylsulfoxide (DMSO), ethyl acetate, or acetonitrile. In
addition, the nitrosation may be performed in the presence or
absence of an amine base such as pyridine or triethylamine.
Alternatively, the nitrosation of the compound of the formula 16
may be performed with nitrous acid generated in situ from sodium
nitrite and hydrochloric acid in an aqueous or mixed aqueous and
organic solvent system to afford a compound of the formula IA.
[0123] Nitric oxide adducts of the formula 1B wherein b is an
integer from 270 to 500, c is an integer of 1 to 2, D is a thiol
containing amino acid or peptide of 1 to 10 amino acids containing
1 to 10 thiols or a thiol containing carboxylic acid containing 1
to 10 thiol groups, a is an integer from 1 to 10, and b and c are
defined as above may be prepared according to the reaction scheme
depicted in FIG. 1B, in which the biodegradable poly L-lactic
acid/poly-L-lysine copolymer prepared as described by Berrera et
al. is representative of the synthetic polymeric materials defined
above. The primary amino groups of the compound of the formula 13
wherein b and c are defined as above may be acylated with a
compound of the formula 17 wherein Q is halogen, imidazolyl, or
trihalomethoxy in a suitable inert solvent or mixture of solvents
such as DMSO and methylene chloride to afford a compound of the
formula 18. The compound of the formula 18 is then reacted with a
compound of the formula 19 wherein D and a are as defined above to
afford a compound of the formula 20. The compound of the formula 20
is then nitrosated to afford a compound of the formula 1B with a
suitable mild nitrosating agent such as nitrosyl chloride or
nitrosonium tetrafluoroborate in an inert organic solvent or
mixture of inert solvents such as methylene chloride, chloroform,
dimethyforamide (DMF), dimethylsulfoxide (DMSO), ethyl acetate, or
acetonitrile. In addition, the nitrosation may be performed in the
presence or absence of an amine base such as pyridine or
triethylamine. Alternatively, the nitrosation of the compound of
the formula 20 may be performed with nitrous acid generated in situ
from sodium nitrite and hydrochloric acid in an aqueous or mixed
aqueous and organic solvent system to afford a compound of the
formula 1B.
[0124] Another example of a nitric oxide adduct derived from a
synthetic polymeric material is the modification of the L-cysteine
amino acid residues immobilized to modified surface of
poly(ethyleneterephalate) which has been activated by pretreatment
with 3-aminopropyltriethoxysilan- e followed by glutaraldehyde as
described by Bui et al., The Analyst, 118:463 (1993). The cysteine
thiols may be nitrosated with a suitable nitrosating agent such as
nitrous acid generated in situ from sodium nitrite and hydrochloric
acid in an aqueous or mixed aqueous and organic solvent system or,
alternatively, with nitric oxide gas or nitrosyl chloride in a
suitable inert solvent to afford the polymer containing the nitric
oxide adduct.
[0125] Yet another embodiment of a nitric oxide adduct pertains to
the derivatization of a gold or gold coated surface with a
self-assembled monolayer (SAMS) of an omega-substituted
alkanethiolates or mixture of omega-substituted alkanethiolates or
omega-substituted alkanethiolates and unsubstituted
alkanethiolates. Functionalized surfaces of SAMS terminating in
carboxylic acids [Collison et al. Langmuir, 8:1247, 1992,; Leggett
et al., Langmuir, 9:2356, 1993] or amines [Whitesell et al., Angew.
Chem. Int. Ed. Engl., 33:871, 1994] have previously been prepared.
These functionalized SAMS may be further derivatized with organic
groups containing one or more nitric oxide adducts as depicted in
FIG. 22.
[0126] For example, the amine groups of the SAMS surface composed
of the compound of the formula 23 wherein e is an integer from 2 to
20 may be reacted with a compound of the formula 14 wherein T, E, d
and P.sup.1 are defined as above to afford a SAMS surface composed
of a compound of the formula 24. After deprotection of the thiol
moieties of the compound of the formula 24, the free thiol groups
are nitrosated to afford a compound of the formula IIB using a
suitable mild nitrosating agent such as nitrosyl chloride or
nitrosonium tetrafluoroborate in an inert organic solvent or
mixture of inert solvents such as methylene chloride, chloroform,
dimethyformamide (DMF), dimethylsulfoxide (DMSO), ethyl acetate, or
acetonitrile. In addition, the nitrosation may be performed in the
presence or absence of an amine base such as pyridine or
triethylamine. Alternatively, the nitrosation of the free thiol
groups may be performed with nitrous acid generated in situ from
sodium nitrite and hydrochloric acid in an aqueous or mixed aqueous
and organic solvent system to afford a compound of the formula
II.
[0127] Particularly preferred nitric oxide adducts are
polynitrosylated peptides and proteins. Synthesis of polynitrosated
peptides and proteins can be achieved in several ways. 1) Mono
S-nitrosylation is best achieved by incubating peptides and
proteins (in deionized water in an equimolar concentration of
acidified nitrite (final concentration 0.5 N HCl) for a period of
1-30 minutes. The incubation time depends on the efficiency of
nitrosation and the tolerance of the protein. Nitrosation can also
be achieved with a variety of other nitrosating agents including
compounds such as S-nitroso-cysteine, S-nitroso-glutathione and
related alkyl nitrites. These compounds are to be used when the
peptide or protein does not tolerate harsh acidic conditions, e.g.
human hemoglobin.
[0128] There are two principal ways of achieving poly
S-nitrosation. In the first, the peptide or protein is reduced in
100-1000 molar excess dithiothreitol for 30-60 minutes. This
exposes intramolecular thiols. The peptide or protein is separated
from dithiothreitol by gel filtration (G-25). The protein is then
exposed to increasing concentrations of acidified nitrite (0.5 N
HCl) in relative excess over protein. Complementary measurements of
Saville indicate when S-nitrosation is complete. For example, with
albumin, this procedure leads to approximately 20 intramolecular
S--NO derivatives.
[0129] Alternatively, the protein can be treated with thiolating
agent such as homocysteine thiolactone. This tends to add
homocystine groups to exposed amine residues in proteins. The
derivatized protein can then be S-nitrosated by exposure to
acidified nitrite. Exposure to increasing concentrations of nitrite
with complementary measurements of Saville can be used to ascertain
when S-nitrosation is maximal. Alternatively, thiol groups can be
quantified on the protein using standard methodologies and then the
protein treated with a stoichiometric concentration of acidified
nitrite (0.5 N HCl).
[0130] Polynitrosation of nucleophilic functional groups (other
than thiol) can be achieved when proteins are incubated with excess
acidified nitrite. The order of protein reactivity is tyrosine
followed by amines on residues such as trytophan. Amide linkages
are probably less reactive. Accordingly, many NO groups can be
added to proteins by simply incubating the protein with high excess
acidified nitrite. For example, exposure of albumin to 1000 fold
excess nitrite leads to approximately 200 moles of NO/mole protein.
These experiments are performed in 0.5 normal HCl with incubations
for approximately one hour. .sup.15N NMR can be used to determine
where the addition (or substitution) by NO takes place.
[0131] Finally, nitrosation can be achieved by exposure to
authentic nitric oxide gas under anaerobic conditions. For
successful nitrosation proteins should be incubated in at least 5
atmospheres of NO gas for several hours. Incubation time is protein
specific. This can lead to NO attachment to a variety of protein
bases. Best characterized reactions involve primary amines. This
mechanism provides a pathway to sustain N-nitrosation reactions
without deamination. Specifically, exposure to acidified nitrite
would otherwise lead to deamination of primary amines whereas this
method leads to formation of N-hydroxynitrosamines with potent
bioactivity. Similar substitutions at other basic centers also
occur.
[0132] The method of the invention provides significant advantages
over current attempts to reduce platelet deposition on artificial
surfaces. As demonstrated by the inventors, a surface can be coated
with nitric oxide adducts using simple, effective methods. The
coated surfaces may be used immediately, or stored and used at a
later date. In addition, by coating the surface itself, this method
eliminates the need for systemic administration of
anti-thrombogenic agents which are often ineffective, have serious
adverse side effects, or are unsuitable for use in certain
patients. Also, the inhibition of platelet deposition provided by
the invention is completely and immediately reversible, a need
which is especially important in patients with cardiac or vascular
disease.
[0133] By preventing platelet deposition or thrombus formation, the
invention is also useful in preventing serious vascular
complications associated with the use of medical devices. These
complications occur as a result of increased platelet deposition,
activation, and thrombus formation or consumption of platelets and
coagulation proteins. Such complications are well known to those of
ordinary skill in the medical arts and include myocardial
infarction, pulmonary thromboembolism, cerebral thromboembolism,
thrombophlebitis, thrombocytopenia, bleeding disorders and any
additional complication which occurs either directly or indirectly
as a result of the foregoing disorders.
[0134] In another embodiment, the invention relates to a method for
preventing the deposition of platelets on a surface comprising
contacting the surface with a nitric oxide adduct in combination
with at least one additional anti-thrombogenic agent. The term
"anti-thrombogenic" agent refers to any compound which alters
platelet function, or interferes with other mechanisms involved in
blood clotting, such as fibrin formation. Examples of such
compounds include, but are not limited to, heparin, warfarin,
aspirin, indomethacin, dipyridamole prostacyclin,
prostaglandin-E.sub.1 or sulfinpyrazone.
[0135] This method for coating a surface with a nitric oxide adduct
in combination with another anti-thrombogenic agent will be
accomplished using the methods described previously for coating a
surface with a nitric oxide adduct alone, and are suitable for any
and all types of natural tissue and artificial surfaces. The
appropriate coating concentration of the other anti-thrombogenic
compound is determined using routine methods similar to those
described previously. The coated surfaces may be used in the same
manner described for those surfaces coated with nitric oxide
adducts alone.
[0136] By coating a surface with a nitric oxide adduct in
combination with at least one other anti-thrombogenic agent, one
will be able to not only prevent-platelet deposition, which is the
initial event in thrombus formation, but also to limit fibrin
formation directly, by inhibiting factor VIII, and platelet granule
secretion, and indirectly, by inhibiting plasminogen activator
inhibitor (PAI-1) release from platelets. Thus, by coating a
surface with agents that both prevent platelet deposition and
interfere with other platelet functions which contribute to
coagulation, the invention provides a further means for preventing
thrombus formation.
[0137] In a further embodiment, the invention relates to a method
for preventing thrombus formation on a damaged vascular surface in
an animal, comprising applying a nitric oxide adduct directly to
the damaged surface. The term "damaged vascular surface" refers to
any portion of the interior surface of a blood vessel in which
damage to the endothelium or subendothelium, narrowing or stenosis
of the vessel has occurred. The invention is especially suitable
for use in coronary arteries, but is beneficial in other damaged
arteries and also in veins including particularly those used in
arterial or venous bypass replacement where they are susceptible to
damage from the typically higher arterial pressures to which they
are unaccustomed.
[0138] The nitric oxide adduct is applied directly to the damaged
vascular surface by using an intraarterial or intravenous catheter,
suitable for delivery of the adduct to the desired location. The
location of damaged arterial surfaces is determined by conventional
diagnostic methods, such as X-ray angiography, performed using
routine and well-known methods available to those of skill within
the medical arts. In addition, administration of the nitric oxide
adduct using an intraarterial or intravenous catheter is performed
using routine methods well known to those in the art. Typically,
the preparation is delivered to the site of angioplasty through the
same catheter used for the primary procedure, usually introduced to
the carotid or coronary artery at the time of angioplasty balloon
inflation.
[0139] The compounds of this invention can be employed in
combination with conventional excipients, i.e., pharmaceutically
acceptable organic or inorganic carrier substances suitable for
parenteral application which do not deleteriously react with the
active compounds. Suitable pharmaceutically acceptable carriers
include, but are not limited to, water, salt solutions, alcohol,
vegetable oils, polyethylene glycols, gelatin, lactose, amylose,
magnesium stearate, talc, silicic acid, viscous paraffin, perfume
oil, fatty acid monoglycerides and diglycerides, petroethral fatty
acid esters, hydroxymethylcellulose, polyvinylpyrrolidone, etc. The
pharmaceutical preparations can be sterilized and if desired, mixed
with auxiliary agents, e.g., lubricants, preservatives,
stabilizers, wetting agents, emulsifiers, salts for influencing
osmotic pressure, buffers, colorings, flavoring and/or aromatic
substances and the like which do not deleteriously react with the
active compounds. For parenteral application, particularly suitable
vehicles consist of solutions preferably oily or aqueous solutions,
as well as suspensions, emulsions, or implants. Aqueous suspensions
may contain substances which increase the viscosity of the
suspension and include, for example, sodium carboxymethyl
cellulose, sorbitol, and/or dextran. optionally, the suspension may
also contain stabilizers.
[0140] The term "therapeutically effective amount," for the
purposes of the invention, refers to the amount of the nitric oxide
adduct which is effective to achieve its intended purpose. While
individual needs vary, determination of optimal ranges for
effective amounts of each nitric oxide adduct is within the skill
of the art. Generally, the dosage required to provide an effective
amount of the composition, and which can be adjusted by one of
ordinary skill in the art will vary, depending on the age, health
physical condition, sex, weight, extent of disease of the
recipient, frequency of treatment and the nature and scope of the
desired effect. The preparations, which are suitable for treatment
of artificial surfaces, such as of a medical device, and
endothelium are used in concentrations of about 500-700 mM of
adduct delivered by drip infusion sterile in a physiological liquid
over 2-3 minute periods in amounts of 2-3 ml per 25 kg body
weight.
[0141] As demonstrated by the inventors, direct application of a
nitric oxide adduct to a damaged vascular surface, coats the
surface, thereby decreasing the thrombogenicity of the surface. As
further demonstrated by the inventors, local application of the
nitric oxide adduct to the damaged vascular surface can be
accomplished at doses much lower than those required to exert a
systemic effect. Thus, this method provides a significant and an
unexpected advantage over the use of systemic anti-thrombogenic
agents to prevent thrombus formation in damaged vessels.
EXAMPLE 1
[0142] NO Adducts Make Artificial Surfaces Less Thrombogenic
[0143] One of the best ways to demonstrate that an artificial
surface exposed to blood has been made less thrombogenic is to
measure or quantitate the number of blood platelets that collect on
that surface. This method requires the removal of platelets from an
animal or human subject. The platelets are labeled with a
radioactive material such as Indium.sup.111, which emits gamma
rays, detectable by a gamma counter placed 3 to 6 inches away from
the source of radioactive platelets. The labeled platelets are
either reinjected into the animal or human in vivo, or contacted
with the artificial surface in viva. Platelets will adhere to
artificial surfaces or acutely damaged arterial surfaces. Thus, the
number of normal platelets and radioactive platelets which stick to
the surface is an indication of the thrombogenicity of the
surface.
[0144] The inventors have used this methodology in experiments to
demonstrate that nitric oxide adducts decrease the thrombogenicity
of an artificial surface or a damaged natural arterial surface. The
following experiments demonstrate that coating artificial surfaces,
such as synthetic vascular graft material, with a nitric oxide
adduct, decreases platelet deposition and makes the surface
significantly less thrombogenic than previously used agents such as
albumin alone. In addition, the experiments demonstrate that
polyvinyl chloride (PVC) tubing, which is used extensively in
artificial kidney and heart-lung machines, can be coated with an
nitric oxide adduct such as S-nitroso-albumin, to make it less
thrombogenic.
[0145] Protection of Synthetic Vascular Grafts
[0146] First, the inventors coated dacron grafts and cardiac
catheters with S-nitroso-bovine serum albumin (BSA). In three
separate experiments, an identical pair of 6 mm (internal diameter)
knitted dacron grafts, 5 cm. in length, were prepared for surgical
placement in the transected carotid arteries of three anesthetized
dogs. No heparin was given. One graft was soaked in 5% BSA and the
other graft was soaked in 5% BSA combined with 0.5 mM nitric oxide
(producing S-nitroso-BSA) for one hour prior to insertion, and then
rinsed in saline. The grafts were sutured in place with a
continuous 6-0 proline suture.
[0147] Indium-labeled Platelets
[0148] Indium.sup.111-labeled platelets are very useful in
detecting platelet accumulation on vascular grafts. Therefore,
Indium.sup.111-labeled platelets were prepared according to
standard methods described in Heyns "Method for Labeling Platelets
with In.sup.111-oxine". In: Platelet Kinetics and, Imaging Vol. II,
Editors Heyns et al., CRC Press, 1985; and Sheffel et al., J. Nucl.
Med., 20: 524-531, 1979, and injected prior to insertion of the
grafts. Following graft insertion, the dogs were observed for two
hours, then both grafts were removed, rinsed, and weighed. The
grafts were then placed in a Nal gamma well counter and counted for
four minutes.
[0149] The three grafts coated with BSA alone had an average of
654,000+/-89,000 counts/4 minutes. In contrast, the three grafts
coated with S-nitroso-BSA had an average of 278,000+/57,000
counts/4 minutes (P<0.005). The average percent increase in
weight for the three grafts due to thrombus formation on the
luminal surface with BSA alone, was 410%+/-97%, while the percent
increase in weight for the three grafts incubated with nitroso-BSA
was 196%+/-71% (P<0.005).
[0150] These data show that during exposure of the graft to
circulating blood over a period of two hours, there was
considerably less platelet deposition and clotting on the synthetic
grafts treated with S-nitroso-BSA. Thus the results demonstrate
that S-nitroso-BSA coating of synthetic vascular grafts provides
protection against early platelet deposition.
[0151] In addition, three pairs of 5 FR USCl catheters were
studied. One catheter was soaked in 5% BSA, while the other
catheter was soaked in a mixture of S-nitroso BSA for one hour. The
catheters were rinsed with saline and one each was inserted into
the right or left femoral arteries of the dogs described above, and
left for two hours. Each catheter was flushed with normal saline
every one-half hour, but no heparin was given. The catheters were
then removed and rinsed with saline. Equal lengths of the catheters
were cut from the distal ends and each one was placed in a Nal
gamma counter and the radioactivity was counted for four
minutes.
[0152] The counts for the three catheters coated with BSA alone had
an average count of 9,000.+-.1,100. In contrast, the three
catheters coated with 5% BSA+0.5 Mm nitric oxide had only
2,850.+-.800 counts. Thus, there were significantly fewer platelets
deposited on the catheters coated with S-nitroso-BSA, than those
coated with BSA alone. These experiments demonstrate that synthetic
vascular grafts coated with S-nitroso-BSA and immediately
implanted, are significantly less thrombogenic than grafts coated
with BSA alone.
[0153] The inventors conducted an additional experiment to
investigate whether S-nitroso-BSA can be used to coat a surface
such as polyvinyl chloride (PVC), and in addition, whether such
surfaces can be treated at one time, and used at a later time. In
this experiment, three pieces of PVC, 3 mm in internal diameter and
2 cm. in length were soaked in BSA for 4 hours, allowed to dry, and
placed in a dark place. Three identical pieces of PVC tubing were
soaked in an S-nitroso-BSA solution for 4 hours, dried, and also
placed in the dark. The lengths of PVC tubing were kept in the dark
to minimize potential inactivation of the nitric oxide-donating
compounds caused by exposure to light.
[0154] Three days after coating, a pair of PVC tubing pieces, one
coated with BSA, and one coated with S-nitroso-BSA, were placed as
a shunt in each of the two femoral arteries of a dog. The dog was
injected with Indium.sup.111 labeled platelets as previously
described. Two hours after the PVC shunts were placed in the
circulation with radioactive platelets, they were removed and
placed in the Nal gamma counter.
[0155] The counts on the BSA coated shunt were 200,870/4 minutes,
whereas on the S-nitroso-BSA coated graft, the counts were only
97,510/4 minutes. Thus, the shunts coated with S-nitroso-BSA have
significantly fewer platelets deposited on its internal surface
than the one coated with nitroso-BSA.
EXAMPLE 2
[0156] Na Nitroprusside Coated Damaged Arterial Surfaces are Less
Thrombogenic
[0157] The following experiments demonstrate that nitric
oxide-donating compounds, such as sodium nitroprusside and
S-nitroso-BSA, can be applied directly to damaged arterial or
venous surfaces (blood vessels) to inhibit platelet deposition and
thrombus formation.
[0158] The inventors developed an animal model which allows them to
mimic a patient with narrowing of the coronary or other arteries
and arterial damage caused by atherosclerosis or after angioplasty,
atherectomy or other procedure. The model uses anesthetized dogs
with open chest and exposed heart. Briefly, an electromagnetic flow
probe is placed on the coronary artery to continuously measure
blood flow through the artery. Then the arterial wall is damaged
(intima and media) by clamping the artery several times with a
surgical clamp. In the area of arterial damage, a plastic
encircling cylinder is placed around the outside of the coronary
artery to produce a 70% narrowing or reduction in the lumen
gradually diameter. This mimics atherosclerotic narrowing of
arteries in patients. Platelet-mediated thrombi periodically form
in the stenosed lumen, gradually cutting off the coronary blood
flow. Subsequently, the thrombi embolize distally and blood flow is
restored. This process, which occurs periodically, produces
cyclical reductions in flow, hereinafter referred to as "cyclic
flow reductions" (CFRs). If no action is taken to prevent platelet
interaction with the damaged arterial wall, these CFRs will
continue to occur for many hours.
[0159] The inventors have determined that CFRs represent an
interaction between platelets and the clotting system, and damaged
endothelial cells in narrowed or stenosed arterial walls. In
addition, CFRs occur in human arteries which are narrowed by
atherosclerosis, and the resulting periodic clot formation can
cause chest pain or leg pain in patients with atherosclerotic
narrowing of coronary or leg arteries. Finally, the CFRs due to
platelet-mediated clotting can be exacerbated by further damage to
the arterial wall.
[0160] During the course of this study it was observed that when
arterial wall was damaged initially by clamping the artery with a
surgical clamp, platelet thrombi formed, and CFRs were produced. As
a result of this observation, the following experiments were
conducted to determine if direct infusion of an NO donor such as
sodium nitroprusside can make a damaged arterial wall less
thrombogenic.
[0161] The following experiments demonstrate that nitric
oxide-donating compounds, such as sodium nitroprusside and
S-nitroso-BSA can be applied directly to damaged arterial surfaces
(blood vessels) to inhibit platelet deposition and thrombus
formation.
[0162] In five anesthetized dogs, both carotid arteries were
exposed. Two 3 FR USCl catheters were prepared for arterial
implantation. One catheter was soaked in a 5% BSA solution for 12
hours, while the other was soaked in a 5% BSA solution which also
contained 1 mg/ml of sodium nitroprusside. One each of the two
coated catheters was placed randomly in the right or left carotid
artery of the dog through a small incision sealed with a 6-0
proline suture. The catheters were advanced for 5 cm into the
arterial lumen. The dogs were not given any heparin. The catheters
were removed 6-8 hours later and examined for clotting on the
catheter wall and at the site where the catheter entered the
carotid wall. There was considerably more clotting on the
BSA-coated catheter compared to the catheter coated with BSA plus
sodium nitroprusside.
[0163] In five open-chested anesthetized dogs, the coronary artery
was dissected out and instrumented for measuring CFRs as previously
described. The inventors observed that intravenous infusion of
sodium nitroprusside directly into the artery (at a dose of between
4 and 10 .mu.g/kg/min. for up to 30 minutes) resulted in a decrease
in vivo platelet activity and CFRs were abolished. In addition, the
circulating nitroprusside appeared to coat the damaged arterial
wall, thus making it less thrombogenic. The CFRs were observed to
continue until the sodium nitroprusside infusion had been given for
15 minutes. Then, the CFRs ceased, which suggests that the
platelets were no longer adhering to the arterial wall. The sodium
nitroprusside intravenous infusion was then stopped. The direct in
vivo inhibition of circulating platelets normally stops within
10-15 minutes. However, after the in vivo inhibition of the
platelets by the presence of circulating sodium nitroprusside was
gone, the CFRs did not return. This indicates that the previously
circulating sodium nitroprusside left a protective coating on the
previously damaged arterial surface. The inventors have termed this
protective coating process "passivation."
[0164] The inventors then showed that if one gently rolls the
artery between the fingers, the CFRs return immediately. This
suggests that the protective coating provided by sodium
nitroprusside, has been removed from the internal surface of the
previously damaged artery, thus, allowing platelets to resume
interaction with the unprotected arterial wall and produce CFRS. In
order to demonstrate that this was a local phenomenon affecting the
damaged artery, and not due to a systemic effect inhibiting all the
circulating platelets, the following experiments were
performed.
[0165] Open-chest anesthetized dogs were studied. In the dog, and
also in humans, the two major branches of the main left coronary
artery which are approximately equal in size, are called the left
circumflex (circ) and the left anterior descending (LAD), coronary
arteries. In the experiments, both branches were instrumented with
a flow measuring device, were given equal arterial wall damage
(endothelial and medial damage), and had encircling plastic
cylinders placed on them to produce equal amounts of narrowing or
stenosis.
[0166] Following the induction of damage in both coronary arterial
branches, CFRs were observed in both the LAD branch and the
circumflex branches of the left coronary artery, indicating that
the circulating platelets were adhering to both the narrowed part
of the damaged circumflex artery and also to the damaged LAD
artery. Sodium nitroprusside (10 mg/kg) was then infused directly
into the circumflex coronary artery over 30 seconds. Following the
infusion, the CFRs in the circ disappeared while they continued in
the LAD coronary artery. This demonstrates that the sodium
nitroprusside had a local protective effect on the damaged circ,
and that the dose of sodium nitroprusside was not high enough to
affect circulating platelets or, after recirculation dilution, to
protect the damaged LAD wall.
[0167] CFRs due to platelets adhering and aggregating on the
damaged arterial walls were observed in both arteries, each
independent of the other. Therefore, by injecting the sodium
nitroprusside into the circumflex branch, the inventors were able
to coat this damaged artery directly. In addition, the circulating
concentration of sodium nitroprusside remaining after local
infusion appears to be too low to have a systemic effect on
platelets. Thus, the inventors demonstrated that the protective
effect exerted by localized application of sodium nitroprusside is
a local effect, and can be applied directly to protect particular
segments of a damaged artery.
[0168] Experiments identical to those described above were repeated
using a nitric oxide-bovine serum albumin adduct (BSA-NO) (with
approximately 0.5 mM NO concentration) given selectively into the
circumflex coronary artery. The inventors show that using BSA-NO as
the NO adduct provides better passivation and the effect lasts
longer. When the protective BSA-NO coating has been on the damaged
arterial wall for 4 to 5 hours, the BSA can be recharged with new
NO molecules by infusing sodium nitroprusside intravenously (5-10
.mu.g/kg for 20 minutes) or directly into the coronary artery (10
mg/kg for 30 seconds).
EXAMPLE 3
[0169] pS-NO-BSA Treats Vascular Injury
[0170] Materials: Sulfanilamide and N-(1-naphthyl) ethylenediamine
dihydrochloride were purchased from Aldrich Chemical Co.,
Milwaukee, Wis. Sodium bicarbonate, sodium chloride, sodium
phosphate, sodium nitrite, potassium phosphate-monobasic, 40%
formaldehyde solution and sucrose were purchased from Fischer
Scientific, Fairlawn, N.J. Sephadex G25 was purchased from
Pharmacia, Piscataway, N.J., IODO-BEADS were purchased from Pierce,
Rockford, Ill. and Na[.sup.125I] from New England Nuclear, Boston,
Mass. [.sup.111In] oxine was purchased from Amersham, Arlington
Heights, Ill. Monoclonal mouse anti-proliferating cell nuclear
antigen was purchased from Dako A/S, Denmark. All other chemicals
were purchased from Sigma Chemical Co., St. Louis, Mo.
[0171] Citrate-phosphate-dextrose anticoagulant solution (CPD)
contained 10 mM citric acid, 90 mM trisodium citrate, 15 mM
NaH.sub.2PO.sub.4H.sub.- 2O, and 142 mM dextrose, pH 7.35.
Tris-buffered saline consisted of 10 mM
tris[hydroxymethyl]aminoethane, pH 7.4, and 150 mM NaCl.
Acid-citrate-dextrose contained 100 mM trisodium citrate and 142 mM
dextrose, pH 6.5. Phosphate-buffered saline contained 10 mM sodium
phosphate and 150 mM NaCl, pH 7.4.
[0172] Synthesis of S-nitroso-species: S-NO-BSA was synthesized as
previously described. Fatty acid-free bovine serum albumin (200
mg/ml) was exposed to a 1.4 molar-fold excess of NaNO.sub.2 in 0.5
N HCl for 30 minutes at room temperature and neutralized with an
equal volume of TBS and 0.5 N NaOH. Thiolated bovine serum albumin
(pS-BSA) was prepared after Benesch and Benesch. Briefly, essential
fatty acid-free bovine serum albumin (50 mg/ml) was dissolved in
water with N-acetyl-homocysteine thiolactone (35 mM) and 0.05%
polyethylenesorbitan monolaurate. Equimolar silver nitrate was
slowly added at room temperature over 90 minutes at pH 8.5. Excess
thiourea (70 mM) was added and the pH lowered to 2.5. Excess silver
nitrate was removed by Dowex 50 chromatography with the mobile
phase consisting of 1 M thiourea, pH 2.5, and excess thiourea was
removed by Sephadex G-25 chromatography. pS-BSA was prepared within
two days of nitrosylation and stored at 4"C. Nitrosylation of
PS-BSA was accomplished with 3.6 mM NaNO.sub.2 in 0.5 HCl for 30
minutes at room temperature. The solution was adjusted to pH 4.0
with 0.5 NAOH after nitrosylation. In platelet binding studies, 0.1
mM EDTA was added to pS-BSA prior to nitrosylation.
[0173] The content of S-nitrosothiol was determined by the method
of Saville (Wistow et al., J. Nuci. Med. 19:483-487, 1978). Protein
content was determined using the method of Lowry and colleagues
(Marcus Salier, FASEB.J., 7:516-522, 1993).
[0174] Preparation of [.sup.125I]-labeled S-NO-BSA and [.sup.111In]
labeled platelets: BSA (0.1 mg/ml) was combined with two IODO-BEADS
and 0.1 mCi of Na[.sup.125I]. The solution was incubated for 45
minutes and unincorporated Na[.sup.125I] was removed by gel
filtration with Sephadex G25 equilibrated with TBS containing 0.1
mg/ml BSA. [.sup.125I] BSA had a specific activity of
5.7.times.10.sup.6 cpm/.mu.g and was S-nitrosylated as described
for unlabelled BSA to achieve a final specific activity of
4.times.10.sup.4 cpm/mg BSA. [.sup.111In]-labeling of platelets was
performed after the method of Wistow and colleagues.
[0175] Animal Preparation: All animal preparations were performed
within the institutional guidelines of the Brockton/West Roxbury
Department of Veteran Affairs Medical Center and Boston University
Medical Center, and in accordance with the guiding principles of
the American Physiological Society. New Zealand white rabbits
(3.5-4.2 kg) of either sex were premedicated with 5 mg/kg
intramuscular (IM) xylazine hydrochloride (Miles Pharmaceuticals,
Shawnee Mission, Kans.), and 0.1 mg/kg subcutaneous (SC) atropine
sulfate (Lyphomed, Deerfield, Ill.) fifteen minutes prior to the
induction of anesthesia. Anesthesia was induced with 40 mg/kg IM
ketamine hydrochloride (Fort Dodge Laboratories, Fort Dodge, Iowa)
and 5 mg/kg IM acepromazine maleate (Aveco Company, Inc., Fort
Dodge, Iowa). Additional doses of ketamine hydrochloride were
administered as necessary to maintain anesthesia. For survival
studies, 100,000 U penicillin G (Apothecon of Bristol-Myers Squibb,
Princeton, N.J.), was administered IM perioperatively. The skin
over the femoral arteries was next infiltrated with 1% lidocaine
(Astra Pharmaceuticals, Inc., Westborough, Mass.) and the common
femoral arteries were exposed from the inguinal ligament to the
superficial femoral artery. Arteries were cleared of connective
tissue, side branches were ligated, and the superficial femoral
artery was suspended with silk ties. A 1.5-to-2.0 cm length of
femoral artery was isolated from the circulation proximally and
distally with neurosurgical microaneurysm clips. The superficial
femoral artery was cannulated with a 2 F Fogarty balloon catheter
(American Edwards Laboratories, Santa Ana, Calif.) that was passed
into the isolated segment of femoral artery. The balloon was
inflated with sufficient air to generate slight resistance and
withdrawn three times. A 20 g angiocath was then inserted in the
arteriotomy and 1 ml of 25.8 mg/ml PS-NO-BSA or 49.2 mg/ml S-NO-BSA
was administered over 15 minutes. The contralateral femoral artery
was prepared identically and an appropriate control (25.8 mg/ml
pS-BSA, 49.2 mg/ml BSA or 0.66 mg/ml sodium nitroprusside) was
administered. For binding studies, 0.5 ml of [.sup.125I]-labeled
nitrosylated albumin or control was administered. Following
administration of the agent, the superficial femoral artery was
ligated and flow reestablished. Sham-operated animals underwent
surgical exposure and sidebranch ligation, but no balloon injury
was performed or local delivery administered. The area of balloon
injury was marked by surgical staples in the adjacent muscle
fascia. For chronic studies, the incision was closed with
subcuticular absorbable suture and the animals allowed to recover.
For acute studies, blood was allowed to circulate through the
treated areas for 15 minutes prior to vessel harvest. In some
experiments, a distant control vessel, the right carotid artery,
was isolated and harvested without any other manipulation.
[0176] cGMP analysis: Whole blood was obtained from fasting human
volunteers and platelet-rich plasma (PRP) was prepared by
centrifugation. Platelet counts were determined using a Coulter
counter model ZM (Coulter Diagnostics, Hileah, Fla.). After balloon
injury and treatment with pS-NO-BSA or PS-BSA, arterial segments
were harvested and 2-mm segments were incubated with 100 .mu.l of
PRP containing 10 .mu.M isobutylmethylxanthine. After 1 minute, an
equal volume of ice-cold 10% trichloroacetic acid was added to each
aliquot and the sample vortexed. Enzyme-linked immunoassay of cGMP
was then performed (Cayman Chemical Company, Ann Arbor, Mich.).
Separate 2 mm vessel segments were also assayed for tissue cGMP
after treatment with ice-cold 10% trichloroacetic acid and
sonication (Heat Systems-Utrasonics, Inc., Plainview, N.Y.).
[0177] Tissue processing and analysis: On the 14th postoperative
day, animals were euthanized with 120 mg/kg intravenous sodium
pentobarbital (Anpro Pharmaceuticals, Arcadia, Calif.), and the
abdominal aorta and inferior vena cava interrupted by silk ties. A
7F plastic cannula was inserted into the abdominal aorta and the
vessels perfused clear with saline followed by fixation at 100 mm
Hg pressure with 10% buffered formalin. The vessels were stored in
10% buffered formalin and the samples paraffin-embedded and
microtome-sectioned. Six sections were made along the length of
each injured segment of vessel and stained with Verhoeff s stain
for elastic tissue. The areas within the lumen, internal elastic
membrane, and external elastic membrane were measured by a blinded
observer using computerized digital planimetry (Zeiss, West
Germany). The areas within the lumen, internal elastic membrane and
external elastic membrane were analyzed. Sections with obstructive
thrombus impairing analysis were discarded.
[0178] In a separate set of animals, vessels were perfusion-fixed
with 10% buffered formalin seven days after injury and processed
for analysis of proliferating cells within 12 hours as described
above. Sections were stained for proliferating cell nuclear antigen
and adjacent sections were stained with hematoxylin and eosin. Five
representative sections from each segment were examined. Total
nuclei were counted from the hematoxylin and eosin slides and
percent PCNA positive cells were defined as the number of
PCUA-positive nuclei divided by the total number of nuclei
multiplied by 100.
[0179] [.sup.111In]-labeled platelet studies: Animals were prepared
and treated with pS-NO-BSA or pS-BSA as described above. Five
minutes prior to the release of the vascular clamps, autologous
[.sup.111In]-labeled platelets were infused via the femoral vein,
and the blood was allowed to recirculate for 15 minutes prior to
harvest. Platelet adhesion was quantified with a gamma counter
(Capintec Instruments, Inc., Pittsburgh, Pa.) and normalized to
tissue wet weight.
[0180] Statistics. Data are presented as mean+/-SEM. Treatments
were administered in a paired fashion with one femoral artery
receiving S-nitrosylated protein and the contralateral artery
receiving the appropriate non-nitrosylated control. Sodium
nitroprusside was given to a separate set of animals. Data were
tested for normality using the Kolmogorov-Smimov algorithm and for
equal variance with the Levene Median test. Normally distributed
variables were compared using the paired t-test and non-normally
distributed variables using the Wilcoxon sign-ranks. test or the
Mann-Whitney rank-sum test. Non-paired data were compared using an
independent t-test. Statistical analysis of dose-response was
performed by one-way analysis of variance. Statistical analysis of
dose-response was performed by one-way analysis of variance.
Statistical significance was accepted if the null hypothesis was
rejected with P<0.05.
[0181] Results
[0182] NO content of S-nitrosothiol species: The synthesis of
S-NO-BSA resulted in a final protein concentration of 755 .mu.M
(49.2 mg/ml) and yielded a displaceable NO content of 230.+-.60
.mu.M, yielding a stoichiometry of 0.3.+-.0.08 moles NO/mole
albumin (n=11). Thiolation and S-nitrosylation of BSA produced a
final protein concentration of 391 .mu.M (25.8 mg/ml, n=8) and
yielded a 5.9-fold increase in displaceable NO content with a
maximum content of 2300 .mu.M displaceable NO as compared to
S-NO-BSA. Local delivery consisted of 1 ml of either S-nitrosylated
protein or control solution instilled in the lumen of the femoral
artery.
[0183] S-NO-BSA binding: The binding of locally and systemically
delivered [.sup.125I]-labeled S-NO-BSA to balloon-injured rabbit
femoral artery is shown in FIG. 3. Compared with systemic
administration to an injured artery, local delivery of
[.sup.121I]-S-NO-BSA to the site of injury was associated with a
26-fold increase in binding (140.4+/-3.9.times.10.sup.3 cpm/gm vs.
5.4+/-0.9.times.10.sup.3 cpm/gm, n=4; P=0.029). Endothelial
denudation facilitated S-NO-BSA binding as systemic administration
of [.sup.121I]-S-NO-BSA resulted in significant deposition at the
site of balloon injury compared to an uninjured control vessel
exposed to systemically delivered [.sup.125I]-S-NO-BSA
(5.4.+-.0.9.times.10.sup.3 cpm/gm vs. 3.0+/-0.3 cpm/gm, n=4;
P=0.038).
[0184] pS-NO-BSA effect on platelet binding to injured vessel:
Since platelet adhesion to the injured arterial surface is
important in the proliferative response to injury, we investigated
the effects of pS-NO-BSA on platelet deposition after balloon
injury, the results of which are shown in FIG. 4. The local
administration of pS-NO-BSA reduced the adhesion of
[.sup.111In]-labeled platelets to the injured vessels over
four-fold compared to control (71.3+/-40.4.times.10.sup.3 cpm/gm,
n=6, vs. 16.3+/-6.2.times.10.sup.3 cpm/gm, n=6, P=0.031).
[0185] S-NO-BSA and pS-NO-BSA effects on neointimal proliferation:
Neointimal proliferation after local delivery of S-nitrosylated
proteins and appropriate controls were evaluated by comparing
absolute neointimal area and neointima/media ratios, and are shown
in FIGS. 5A and 5B, respectively. The administration of S-NO-BSA
(containing 0.3.+-.0.1 moles displaceable NO per mole albumin) did
not significantly reduce neointimal area
(2.54+/-0.33.times.10.sup.5 .mu.m.sup.2 vs.
1.83+/-0.18.times.10.sup- .5 .mu.m.sup.2, n=15) or neointima/media
ratio (1.07+/-0.167 vs. 0.72+/-0.084, n=15) 14 days after balloon
injury, although a trend was noted. By contrast, the administration
of pS-NO-BSA (containing 3.2.+-.1.3 moles displaceable NO per mole
albumin) with a greater displaceable NO content did reduce
neointimal area and neointima/media ratio by 81%
(2.24+/-0.328.times.10.sup.5 .mu.m.sup.2 vs.
0.41+/-0.11.times.10.sup.5 .mu.m.sup.2, n=7, P=0.022) and 77%
(0.85+/-0.122 vs. 0.196+/-0.66, n=7, P=0.025), respectively. The
neointimal area (0.23+/-0.07.times.10.sup.5 .mu.m.sup.2) and
neointima/media ratio (0.116+/-0.041, n=7) in the sham operated
animals were comparable to those of the vessels treated with
pS-NO-BSA. Using relatively high concentrations of a conventional
No donor, SNP (2300 .mu.M), we noted a trend towards inhibition of
neointimal proliferation in both neointimal area
(1.47+/-4.15.times.10.sup.5 .mu.M.sup.2, P=0.056) and
neointima/media ratio (0.603+/-0.19, n=5, P=0.11) compared to
control.
[0186] pS-NO-BSA effects on cellular proliferation: Mouse
monoclonal antibody staining against PCNA was used to assay the
degree of SI-phase activity at 7 days after injury. At this time,
no difference in the percent of proliferating cells was noted
between vessels treated with pSBSA (30.1%+/-5.9, n=5) and vessels
treated with pS-NO-BSA (37.8%+/-5.9, n=6). Similarly, no
significant difference was noted in the neointimal proliferation of
the pS-NO-BSA-treated vessels compared to the pS-BSA-treated
controls (neointimal area: 0.124.+-.0.06.times.10.sup.5 .mu.M.sup.2
vs. 0.258+/-0.19.times.10.sup.5 .mu.M.sup.2, n=5, P=0.54, and
neointima/media ratio: 0.032+/-0.005 vs. 0.068+/-0.027, n=5,
P=0.15).
[0187] Displaceable NO effect on neointimal proliferation: Since
S-NO-BSA exhibited a trend toward inhibition and pS-NO-BSA reduced
neointimal proliferation, we examined the relationship between the
amount of displaceable NO and the extent of neointimal response
following vascular injury, and the results are presented in FIGS.
6A and 6B. There was a significant inverse relationship between
displaceable NO and neointimal proliferation as quantified by
absolute neointimal area (P<0.001) (FIG. 6A) and the
neointima/media area ratio (P<0.001) (FIG. 6B).
[0188] pS-NO-BSA treated vessel effect on platelet cGMP and vessel
cGMP: NO inhibits platelets and relaxes smooth muscle cells through
a cGMP-mediated mechanism. We tested the ability of
pS-NO-BSA-treated vessels to deliver No to platelets, and these
results are shown in FIG. 7. Platelet cGMP was significantly
increased after a one-minute exposure to pS-NO-BSA-treated vessels
compared to PS-BSA controls (19.9+/-3.3 vs 4.11+/-0.9 pmol 10.sup.8
platelets, n=14, P<0.001). In addition, vessel CGMP levels were
also elevated after treatment with pS-NO-BSA compared to PS-BSA
control (0.48+/-0.46 vs 0.283+/-0.23 pmol/mg protein, n=3)
suggesting a direct effect on vascular smooth muscle cells, as
well.
[0189] Discussion
[0190] We have previously demonstrated that No combines with
protein sulfhydryl groups to form stable, biologically active
molecules with cGMP-dependent vasodilatory and antiplatelet
properties, both in vitro and in vivo (Stamler et al., Proc. Natl.
Acad. Sci. U S A., 89:444-448, 1992); (Weldinger et al.,
Circulation, 81:1667-1679, 1990). The data presented here
demonstrate that serum albumin, after S-nitrosylation, can bind
avidly to balloon-injured femoral arteries and inhibit neointimal
proliferation. This phenomenon is associated with diminished
platelet deposition at the site of injury through a cGMP-dependent
mechanism. Moreover, the extent of inhibition of neointima
formation is directly related to the quantity of displaceable No
carried by albumin.
[0191] The endothelium is essential for vascular integrity, control
of thrombosis, (Clowes et al., Lab. Invest. 49:327-333, 1983);
(Rees et al., Proc. Natl. Acad. Sci. USA. 86:3375-3378, 1989) and
the regulation of intimal growth (Kubes et al., Proc. Nati. Acad.
Sci. USA, 88:4651-4655, 1991). The endothelium serves these
functions by the production of locally active effector molecules
including EDRF, a compound that has been identified as NO or a
closely related molecule. EDRF is responsible, in part, for many
biologic actions via the activation of guanylyl cyclase, including
relaxation of vascular smooth muscle, (Myers et al., Nature
(Lond.), 345:161-163, 1990); (Kubes and Granger, Am. J. Physiol.
262:H611-H615, 1993) inhibition of platelets, (Radomski et al., Br.
J Pharmacol, 92:181-187, 1987) control of leukocyte adhesion to the
subendothelium, (Reidy, Lab. Invest., 5:513-520, 1985) modulation
of vascular permeability, (Groves et al., Circulation, 87:590-597,
1993) and, perhaps, local control of vascular smooth muscle growth.
Since balloon angioplasty removes the endothelium from arterial
smooth muscle, these endothelial functions are lost during the
procedure. In particular, removal of the endothelium and damage to
the smooth muscle cells are associated with intimal proliferation
(McNamara et al., Biochem. Biophys. Res. Commun., 193:291-296,
1993). The mechanism for this response is complex and involves
platelet deposition and activation, cytokine elaboration, smooth
muscle cell migration and proliferation, and extra-cellular matrix
production. After balloon injury, the endothelium regenerates.
rapidly but is often dysfunctional, and presumably unable to
maintain an adequate antithrombotic, vasodilating, and
antiproliferative phenotype (Saville, Analyst 83:670-672,
1958).
[0192] NO donors have been used with some success in the setting of
balloon injury to produce decreases in intimal proliferation and in
platelet deposition. In the porcine carotid model, Groves and
colleagues (Kubes and Granger, Am. J. Physiol. 262:H611-H615, 1993)
demonstrated reduced platelet adhesion and thrombus formation
locally after systemic administration of SIN-1, a spontaneous NO
donor and metabolite of molsidomine. These authors showed a
2.3-fold reduction in platelet deposition without any significant
hemodynamic changes. Because administration of this agent was
associated with an increase in template bleeding time and in
platelet cGMP, it is possible that SIN-1 exerted its effects
through systemic platelet inhibition. A preliminary report from the
ACCORD trial also suggests that NO donors might be effective
adjuncts for balloon angioplasty in humans (The ACCORD Study
Investigators, J. Am. Coll. Cardiol. 23:59A. (Abstr.), 1994). This
multicenter study evaluated SIN-1 acutely and molsidomine
chronically over six months with diltiazem treatment as a control
arm in patients undergoing balloon angioplasty. The loss index and
binary restenosis rate were significantly improved in the NO
treatment group, although the rate loss was not significantly
different between groups. Chronic supplementation with L-arginine,
a precursor of endothelium-derived nitric oxide, has been shown to
reduce intimal hyperplasia in rabbit thoracic aorta (Cayatte et
al., Arterioscler. Thromb., 14:753-9, 1994) and the rat carotid
artery (von der Leven et al., Clin. Res., 42: 180A. (Abstr.),
1994). By contrast, administration of an inhibitor of NO synthase,
N.sup.G-nitro-L-arginine methyl ester, accelerated neointimal
formation in the setting of balloon injury (Taubman, wall injury.,
Thromb. Haemost., 70:180-183, 1993).
[0193] von der Leven and Dzau recently reported (Zeiher et al.,
Circulation, 88:1-367. (Abstr.), 1993) successful transfection of
the constitutive endothelial-type nitric oxide synthase (eNOS) gene
in a rat carotid injury model. In that preliminary study, eNOS
incorporation and NO production were demonstrable four days after
transfection, and neointimal proliferation was partially inhibited
two weeks after injury and transfection. In our study,
S-nitrosylated albumin was administered acutely and, given its
half-life of 12 hours, (Benesch and Benesch, Proc. Natl. Acad. Sci.
USA, 44:848-853, 1958 it is unlikely that significant amounts of
displaceable NO were still present four days after injury. The
effectiveness of both early and late administration of NO suggests
that NO may influence the complex response to injury by multiple
mechanisms. In addition to modifying the development of platelet
thrombus and the release of growth factors from platelets, local
delivery of S-nitrosothiols could modulate gene transcription in
vascular smooth muscle cells (Lefer et al., Circulation, 88:1-565.
(Abstr.), 1993) as well as smooth muscle metabolism following
injury.
[0194] Our data demonstrate a profound limitation of neointimal
proliferation after a single, local administration of a durable,
potent S-nitrosothiol. Antiplatelet activity may explain these
findings, in part, since we observed a four-fold reduction in
platelet deposition to injured arterial segments after treatment
with pS-NO-BSA. Similarly, we also demonstrated direct platelet
inhibition by the pS-NO-BSA-treated vessel rings. Inhibition of
platelet binding would result in many effects that are likely to
reduce the proliferative response after injury. For example,
platelet adhesion and aggregation is. associated with the release
of PDGF, basic fibroblast growth factor, epidermal growth factor,
and transforming growth factor-beta, potent stimuli for smooth
muscle cell proliferation and matrix production. pS-NO-BSA could
also exert its effect by modulating leukocytes though downregulated
expression of either monocyte chemoattractant protein-I (Hanke et
al., Circ. Res., 67:651-659, 1990) or adhesion molecules (Lefer et
al., Circulation, 88:1-565. (Abstr.), 1993). We cannot exclude a
direct inhibitory effect of NO on vascular smooth muscle gene
expression, migration, proliferation or synthesis of extracellular
matrix.
[0195] The demonstration of unaltered PCNA-positive cells in
vessels treated with pS-NO-BSA compared to control vessels is
intriguing. Hanke demonstrated significant DNA synthesis in the
neointima and media of a rabbit carotid model using electrical
stimulation. Maximal DNA synthesis occurred at approximately seven
days (Hanke et al., Circ. Res., 67:651-659, 1990) and lasted until
at least fourteen days. Our observations suggest a mechanism other
than the inhibition of local cell replication by which to explain
the inhibition of neointimal proliferation in the rabbit injury
model. Such mechanisms could include an early effect on vascular
smooth muscle cell migration, transient inhibition of DNA synthesis
which is not evident on day seven after injury, inhibition of
extracellular matrix production, or inhibition of another factor(s)
required for neointima formation.
[0196] These findings have several implications for the treatment
of human disease. Mechanical removal of the endothelium abolishes
the vasodilator responses to endothelium-dependent vasoactive
stimuli, while leaving the vasoconstrictor effects of agonists to
smooth muscle unopposed (Furchgott Zawadzki, Nature (Lond.).
288-373-376, 1980). This process occurs with balloon angioplasty
especially at sites where platelet thrombus is noted (Uchida et
al., Am. Heart. J., 117:769-776, 1989); (Steele et al., Circ. Res.,
57:105-112, 1985). The strategy of local replacement of an
important endothelial product as therapy for acute thrombotic
phenomena and restenosis following angioplasty is, thus, suggested
by our study.
[0197] In summary, our results demonstrate that a stable NO adduct
of serum albumin binds avidly to balloon-injured subendothelium
when delivered locally. When modified to carry multiple NO groups,
pS-NO-BSA markedly decreases neointimal proliferation after balloon
injury. Local delivery of this molecule decreases platelet adhesion
to the injured subendothelium and directly inhibits the platelet,
interrupting a common pathway through which growth responses are
initiated. These results support the hypothesis that local
supplementation of a long-acting NO donor can favorably modulate
vascular injury. The implications of these findings suggest that
local delivery of S-nitrosothiols may be an effective treatment for
disease states marked by abnormal or absent endothelium, including
restenosis after angioplasty.
EXAMPLE 4
[0198] Porcine Angiographic Stenosis Model
[0199] Pigs were subjected to coronary balloon-injury using
standard methods, in accordance with the protocol illustrated in
FIG. 8. A perforated drug delivery balloon catheter was used at the
time of balloon injury for infusion of polythiolated,
polynitrosated albumin and with albumin control, each of which were
infused at a concentration of 1.5 .mu.M for a period of 15 minutes.
The balloon of the catheter was then deflated and the catheter was
removed. Thereafter, another angiogram was performed to determine,
at 30 minutes after injury, the degree of spasm. Then all catheters
were removed and the incision sites were repaired. The animals were
awakened and maintained with normal chow diets over the next four
weeks. At the end of that period of time, the animals were again
sedated, underwent coronary angiography to determine coronary
stenoses at the site of angioplasty, after which they were
euthanized by an overdose of pentobarbital. Their coronary arteries
perfusion fixed with 100 mm Hg of perfusion pressure. They were
fixed with formalin, harvested and sectioned for quantitative
morphometric assessment of the lumen diameter, the neointimal
dimension and cross-section, as well as the neointimal area. The
arteries were stained with hematoxylin and eosin. The neointima to
lumen diameter ratio was determined and is illustrated by
comparison in FIG. 9.
[0200] In this study, a number of normal cholesterolomic pigs were
subjected to angioplasty and the effect on their coronary artery
was evaluated in groups which received pS-NO-BSA and which received
pS-BSA as a control or placebo. Four weeks after angioplasty, the
animals were sacrificed, their coronary arteries were recovered
with perfusion fixation of the artery at autopsy.
[0201] FIG. 9 is a histogram which illustrates the diameter (mm) of
the neointimal lumen of 14 normocholesterolemic pigs which were
subjected to a balloon angioplasty which induced injury of the
right coronary artery. Thereafter, they received 1.5 .mu.M
pS-NO-BSA or pS-BSA as a control.
[0202] This measurement was made at four weeks into the protocol by
coronary angiography. The animals were sedated, catheters were
placed in the coronary ostea and radiocontrast fluid was infused.
The angiograms were recorded and subsequently processed by a
computer-driven quantitative coronary angiography algorithm to
determine precisely the lumen diameter. The degree of stenosis
represents the percentage reduction in the lumen diameter compared
with a reference segment proximal to the area of stenosis using
standard methods. The results of this are illustrated in FIG.
10.
[0203] FIG. 10 is a histogram which illustrates a degree of
coronary stenosis observed at four weeks after angioplasty in pigs
which received 1.5 .mu.M pS-NO-BSA or pS-BSA as a control.
[0204] This measurement was made during the initial balloon injury
procedure. Within 30 minutes following the procedure, the animals
underwent coronary angiography, coronary catheters were placed in
the coronary ostea, radiocontrast was infused into the coronary
arteries and measurements were made of the degree of so-called
"recoil spasm" that existed at the point of angioplasty. The degree
of spasm or recoil was defined quantitatively, again using the
computer-driven quantitative coronary angiography algorithm that
compared the segment at the site of balloon injury with a proximal
segment that was uninjured as a reference standard. The results are
illustrated graphically in FIG. 11.
[0205] FIG. 11 is a histogram which illustrates the extent of
coronary spasm induced distal the site of injury as compared to the
pre-existing base line in pigs which received 1.5 .mu.M pS-NO-BSA
or pS-BSA as a control.
[0206] Next, a quantitative measurement was made by morphometric
assessment following autopsy and after perfusion fixation of the
vessel to determine lumen diameter at four weeks. The results are
illustrated in FIG. 12.
[0207] FIG. 12 is a histogram which illustrates the inner-diameter
of the lumen of the right coronary artery of pigs four weeks after
they received 1.5 .mu.M pS-NO-BSA or pS-BSA as a control.
EXAMPLE 5
[0208] Coating Palniaz-Schatz Stents with pS NO-BSA
[0209] The experiments recorded here were performed in order to
determine: whether this pS NO-BSA would adhere to the metallic
surface of a Palmaz-Schatz stent; whether there would be enough
nitric oxide available to inhibit platelet adhesion and aggregation
near the metallic surface; whether coating of a Palmaz-Schatz stent
with pS NO-BSA would significantly reduce the deposition of
Indiumn.sup.111 labeled platelets when placed in the carotid
arteries of pigs; whether coating a Palmaz-Schatz stent would
decrease the degree of anticoagulation needed to maintain patency;
and whether the coating would reduce the degree and severity of
neointimal hyperplasia leading to restenosis.
[0210] Palmaz-Schatz stents were dip-coated in 800-1000 .mu.M
SNO-BSA three times for 10 minutes followed by 10 minutes of air
drying time. Then, one week later, three coated stents were
immersed in platelet rich plasma (PRP) for 2 minutes. A control
uncoated stent was also immersed in another aliquot of the same
PRP.
[0211] The increase in platelet cyclic GMP levels was determined
and is shown in Table 1
1TABLE 1 Cyclic GMP Levels in PRP Exposed for 2 Minutes to pS
NO-BSA Coated and Uncoated Palmaz-Schatz Stents (P moles
CGMP/10.sup.8 platelets) Conc of NO (Saville R.sub.x) A B C D 500
.mu.M 7.2 6.8 6.9 6.3 7.0 6.0 6.8 4.6 2.8 2.8 2.4 1.7 800 .mu.M 5.8
5.6 5.9 3.9 10.4 11.0 10.8 8.5 1000 .mu.M 4.6 4.9 5.7 1.9 6.6 5.9
6.3 3.0 5.9 5.1 5.7 2.9
[0212] The three columns on the left (columns A through C) show the
levels of cGMP in the platelets which were exposed to a coated
stent and the column on the right (Column D) shows the level of
cyclic GMP in the same PRP which was exposed to the uncoated
stent.
[0213] A coated and an uncoated stent were placed in the carotid
arteries of pigs, one in each carotid artery. Then Indium.sup.111
labeled platelets were circulated for four hours. At the end of the
four hours, the arteries containing the stents were removed and
placed in a Gamma counter well. The counts on stents indicate the
degree of platelet deposition on each stent. The data is shown in
Table 2.
2TABLE 2 Indium.sup.III Labeled Platelet Counts on S-No-BSA Coated
Versus Uncoated Palmaz-Schatz Stents P S NO-BSA Coated Uncoated
Ratio 59,760 1,076,300 18 94,000 246,000 2.6 126,400 868,600 6.0
61,500 347,400 5.7 120,000 684,000 5.6 88,600 264,462 3.0 135,000
590,000 4.1 14,160 43,900 3.2
[0214] One coated and one uncoated stent was placed in each of the
two carotid arteries under sterile conditions in 10 pigs. They will
be followed for 28 days and then the stented carotid arteries will
be removed. They will be examined histologically for the degree of
neointimal hyperplasia.
* * * * *